Protocol I8H-MC-BDCX (b)
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and 
Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve 
Adults With Type 2 Diabetes
[STUDY_ID_REMOVED]
Approval Date: 13-May-2022
CONFIDENTIAL  I8H-MC-BDCX  (b) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and  Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical 
investigation of  LY3209590 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:
A Phase 3, Parallel -Design, Open-Label, Randomized Control Study to Evaluate the Efficacy 
and Safety of LY3209590  as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin 
Naïve Adults with Type 2 Diabetes  
Protocol Number:  I8H-MC-BDCX  
Amendment Number:  b 
Compound : LY3209590  
Brief Title:  
Efficacy  and Safety of LY3209590 Compared to  Degludec in Adults with Type 2 Diabetes Who 
Are Starting Basal Insulin for the First Time 
Study Phase: 3 
Acronym : QWINT -2 
Sponsor Name:  Eli Lilly and Company  
Legal Registered Address:  Indianapolis, Indiana, USA 46285  
Regulatory Agency Identifier Number(s) : 
IND: 129390  
EudraCT: 2021 -005891 -21 
Document ID:  VV-CLIN -040206  
Approval Date:  Protocol  amendment ( b) Electronically  Signed and  Approved  by Lilly  on date 
provided below.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
2 Medical Monitor Name and Contact Information will be provided separately . 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
3 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Document  Date  
Amendment (a) 15 Feb 2022  
Original Protocol  04 Feb 2022  
Amendment [b] 
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
The primary rationale for the current amendment is to address regulatory feedback regarding 
exclusionary ALT and AST thresholds  and rescue medication . These changes are  detailed in the 
table below.  
Section no and Name  Description of Change  Brief Rationale  
1.1. Synopsis  Edited the subsection s ‘Overall Design ’, 
‘Brief Summary’ , and ‘Intervention 
Groups and Duration’  Correction  
Updated the section to align with the 
changes in  the main body of the protocol  For consistency  
1.2. Schema  Added a note below the schema as 
follows: During the safety follow -up 
period, CGM device will be worn for 4 
weeks (52 to 56), but device return and 
data download will occur a week later (on 
Week 5 7). For clarity  
1.3.1. Screening Visit 1, Lead -
In Visit 2, and Treatment 
Visits 3 -18 In CGM sensor insertion  line, added  
“Participants will be required to replace 
the sensor at designated intervals per the 
investigator instruction.  Additional 
unscheduled visits may be needed for 
participants support” under comments 
column  For clarity  
1.3.2. Treatment Visits 19 to 
31, Early Discontinuation, 
Unscheduled Visits, and 
Safety Follow -up Visits 801 
and 802  In CGM sensor insertion line, added 
“Participants will be  required to replace 
the sensor at designated intervals per the 
investigator instruction.  Additional 
unscheduled visits may be needed for 
participants support” under comments 
column  For clarity  
1.3.2. Treatment Visits 19 to 
31, Early Discontinuation, 
Unsc heduled Visits, and 
Safety Follow -up Visits 801 
and 802  In CGM device return and data download 
line, added “CGM device  will be worn for 
4 weeks (52 to 56), but device return and 
data download will occur a week later (on 
Week 57).”  For c larity 
3. Objectives, Endpoints, and 
Estimands  Removed “Incidence” from the subgroup 
tertiary objective endpoint of Level 1 and 
composite of Level 2 and 3 hypoglycemia 
events during the treatment period  Correction  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
4 3. Objectives, Endpoints, and 
Estimands  Moved the “Evaluation of Immunogenicity 
- Incidence of positive LY3209590 
treatment -emergent anti -drug antibodies” 
under Tertiary Safety Parameters  For consistency  
3. Objectives, Endpoints, and 
Estimands  Removed “Potential intrinsic and extrinsic 
factors” under tertiary objective – 
Characterize the PK/PD of LY3209590  For consistency  
3. Objectives, Endpoints, and 
Estimands  In Primary estimand subsection, United 
States registration, edited the text in 
primary clinical question of interest to 
clarify “study eligibl e” participants  For c larity  
3. Objectives, Endpoints, and 
Estimands  Edited Treatment regimen estimand 
attributes table  
- Population:  added cross reference to 
Section 9.2, and removed other cross 
references  For clarity  
3. Objectives, Endpoints, and 
Estimands  In Primary estimand subsection, 
Registration for countries outside the 
United States, edited the text in primary 
clinical question of interest to clarify 
“study eligible” participants  For c larity  
3. Objectives, Endpoints, and 
Estimands  Edited Efficacy estimand attributes table  
- Population: added cross reference to 
Section 9.2, and removed other cross 
references  For clarity  
4.1. Overall Design  Updated CGM related items to the 
description of the visits  For clarity and consistency  
4.2. Scientific Rationale for 
Study Design  Added “of 52 weeks” to Study Duration 
subsection  For clari ty 
5.1. Inclusion Criteria  In inclusion criteri on 3, added “ as 
determined by central laboratory”  For clari ty 
5.1. Inclusion Criteria  In inclusion criterion 4,  updated the 
language  For clari ty 
5.1. Inclusion Criteria  In inclusion criteri on 8, added a note “The 
use of personal, non -study CGM device 
will not be allowed  For clari ty 
5.2. Exclusion Criteria  In exclusion criteri on 20, increased AST 
and ALT thresholds from 2.5x ULN to 3x 
ULN  To address regulator y feedback  
5.2. Exclusion Criteria  In exclusion criteri on 20, u pdated the 
language of non-alcoholic fatty liver 
disease  For consistency  
5.2. Exclusion Criteria  In exclusion criterion 26, added “glimins”  For clarity  
5.2. Exclusion Criteria  In exclusion criteri on 29, added wording 
“after having signed the ICF” and “after 
receiving at least 1 dose of the study basal 
insulin”  For clarity  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
5 6.1.2. Rescue Medicine for 
Management of Severe or  
Persistent Hyperglycemia  Modified the rescue criteria (timing to 
initiate the rescue therapy) to match the 
program strategy  To address regulator y feedback  
Modified the language in para graphs  1 and 
3; moved para graph  4; and included the 
last two paragraphs  To address regulatory feedback   
6.3. Measures to minimize 
Bias: Randomization and 
Blinding  In the Randomization and stratification 
subsection, added “Yes/No” to the use of 
sulfonylurea and GLP -1 RA at 
randomization  For clarity  
6.5.1.3 . LY3209590 Dose 
Adjustment Based on 
Hypoglycemia Events  Added “over the previous week” to the 
second column heading of the table  For clarity  
6.5.2.3 LY3209590 Dose 
Adjustment Based on 
Hypoglycemia Events  Added “over the previous week” to the 
second column  heading  of the table  For clarity  
6.7. Treatment of Overdose  Added “consider holding sulfonylureas if 
clinically appropriate”  To optimize the overdose 
management guidance  
6.8.3. Antihyperglycemic 
Medications  In the table showing the conditions for use 
of concomitant antihyperglycemic 
medications,  replaced “N” with “See 
Note”  in ‘Rescue Therapy ’ column for 
‘Non -study basal insulins’ and ‘Insulin 
mixtures’ rows ; and added “Note: 
Participants who require a non -study basal 
insulin or insulin mixture as rescue therapy 
must discontinue study basal insulin 
therapy (LY3209590 or insulin degludec). 
The participant will remain in the study 
and follow procedures for the remaining 
study visits ”  For clarity  
6.8.4. Treat ment after Study 
Completion  Added  this new section  To address regulatory feedback   
7.1.2. QTc Stopping Criteria  Removed the section  There is no specific QTc stopping 
criteria due to no known or 
suspected safety -related risk with 
insulins or LY3209590  
8.1.1.2. Continuous Glucose 
Monitoring (CGM) Systems  Updated the section  To address regulatory feedback  
9. Statistical Consideration s  Replaced “Visit 31 (Week 52)” with 
“Week 52 (Visit 31)”  For clarity  
9.2. Analyses Sets  Updated the analysis population/set.  To meet the anticipated 
requirement for excluding 
inadvertently enrolled participants 
in some countries.  
9.3. Statistical Analyses  Made updates according to the changes in 
analyses sets.  As 9.2 and for clarity.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
6 10.4.2. Contraception 
Guid ance Corrected the typo error and added “t hese 
forms of contraception must be used for 
the duration of the study.”  Correction  
10.7. Appendix 7. Country -
specific Requirements  
10.7.3. Germany  Deleted “1 0.1.3. Informed Consent 
Process ” as reference to “legally 
authorized representative,” “legal 
guardian,” “parents”  is not mentioned in 
the protocol amendment.  Correction  
Updated the brief rationale  in the table  
10.9. Appendix 9: 
Abbreviations and Definitions  Added CGM parameters.  To address regulator y feedback  
Removed ‘FAS’  Correction  
Throughout  protocol  Following glucose values in mg/dL, added 
corresponding values in mmol/L . For clarity  
Throughout protocol  Minor editorial and formatting changes  Minor, therefore, not detailed.  
 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
7 Table of Contents  
Protocol Amendment Summary of Changes Table  ................................ ................................ ....3 
1. Protocol Summary  ................................ ................................ ................................ ........ 11 
1.1. Synopsis  ................................ ................................ ................................ .......................... 11 
1.2. Schema  ................................ ................................ ................................ ............................ 15 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 16 
1.3.1.  Screening Visit 1, Lead -In Visit 2, and Treatment Visit s 3-18 ................................ ......17 
1.3.2.  Treatment Visits 19 to 31, Early Discontinuation, Unscheduled 
Visits, and Safety Follow -Up Visits 801 and 802 ................................ ........................... 24 
2. Introduction  ................................ ................................ ................................ ................... 33 
2.1. Study Rationale  ................................ ................................ ................................ ............... 33 
2.2. Background  ................................ ................................ ................................ ..................... 33 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 34 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 34 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 35 
2.3.3.  Overall Benefit Risk Conclusion  ................................ ................................ .................... 35 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......36 
4. Study Design  ................................ ................................ ................................ .................. 41 
4.1. Overall Design  ................................ ................................ ................................ ................ 41 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 43 
4.3. Justification for Dose  ................................ ................................ ................................ ......43 
4.4. End of Study Definition  ................................ ................................ ................................ ..44 
5. Study Population  ................................ ................................ ................................ ........... 45 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 45 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 46 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .48 
5.4. Screen Failures  ................................ ................................ ................................ ................ 49 
5.5. Criteria for Temporarily Delaying Enrollment of a Participant  ................................ .....49 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 50 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 50 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 51 
6.1.2.  Rescue Medicine for Management of Severe or Persistent 
Hyperglycemia  ................................ ................................ ................................ ................ 51 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 52 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 52 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 53 
6.5. Dose Modification  ................................ ................................ ................................ .......... 53 
6.5.1.  LY3209590 Dose Initiation and Adjustment  ................................ ................................ ..53 
6.5.2.  Insulin Degludec Dose Initiation and Adjustment  ................................ .......................... 55 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 56 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...56 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....56 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
8 6.8.1.  Medications with Approved Weight Loss Indication  ................................ ..................... 57 
6.8.2.  Chronic Systemic Glucocorticoid Medication  ................................ ................................ 57 
6.8.3.  Antihyperglycemic Medications  ................................ ................................ ..................... 58 
6.8.4.  Treatment after Study Completion ................................ ................................ .................. 59 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 61 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 61 
7.1.1.  Liver Chemistry Stopp ing Criteria  ................................ ................................ .................. 62 
7.1.2.  Hypersensitivity Reactions  ................................ ................................ ............................. 62 
7.1.3.  Temporary Discontinuation of Study Intervention  ................................ ......................... 62 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ 63 
7.3. Lost to Follow up  ................................ ................................ ................................ ............ 64 
8. Study Assessments and Procedures ................................ ................................ ............. 65 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....65 
8.1.1. Glucose Monitoring  ................................ ................................ ................................ ........ 65 
8.1.2.  Patient -Reported Outcomes  ................................ ................................ ............................ 67 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 70 
8.2.1.  Physical Examinations  ................................ ................................ ................................ ....70 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 70 
8.2.3.  Electrocardiograms  ................................ ................................ ................................ ......... 70 
8.2.4.  Clinical Safety Laboratory Tests  ................................ ................................ .................... 70 
8.2.5.  Hepatic Monitoring  ................................ ................................ ................................ ......... 71 
8.2.6.  Pregnancy Testing  ................................ ................................ ................................ ........... 73 
8.3. Adverse Events, Serious Adverse Events, and Product 
Complaints  ................................ ................................ ................................ ...................... 73 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 75 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 76 
8.3.3.  Cardiovascular Events  ................................ ................................ ................................ ....77 
8.3.4.  Systemic Hypersensitivity Reactions  ................................ ................................ .............. 77 
8.3.5.  Injection Site Reactions  ................................ ................................ ................................ ..78 
8.3.6.  Hypoglycemia  ................................ ................................ ................................ ................. 78 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 79 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 79 
8.6. Genetics  ................................ ................................ ................................ .......................... 79 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 79 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 80 
8.9. Health Economics  ................................ ................................ ................................ ........... 80 
9. Statistical Con siderations  ................................ ................................ ............................. 81 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....81 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..81 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 82 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 82 
9.3.1.  General Considerations  ................................ ................................ ................................ ...82 
9.3.2.  Primary Endpoint or Estimand Analysis ................................ ................................ ......... 83 
9.3.3.  Secondary Endpoints Analysis  ................................ ................................ ....................... 84 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
9 9.3.4.  Tertiary Endpoint(s) Analysis  ................................ ................................ ......................... 85 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 85 
9.3.6.  Other Analysis  ................................ ................................ ................................ ................ 86 
9.3.7.  Subgroup Analyses  ................................ ................................ ................................ ......... 87 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 88 
9.5. Sample Size Determination  ................................ ................................ ............................ 88 
10. Supporting Documentation and Operational C onsiderations  ................................ ..90 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 90 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 90 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 90 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 91 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 91 
10.1.5.  Committees Structure ................................ ................................ ................................ ......91 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 92 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..93 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 94 
10.1.9. Study and Site Start and Closure  ................................ ................................ .................... 95 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 95 
10.1.11.  Investigator Information  ................................ ................................ ................................ .95 
10.1.12.  Sample Retention  ................................ ................................ ................................ ............ 96 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 97 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic  
Hypersensitivity Event  ................................ ................................ ................................ ..100 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ .......... 101 
10.3.1.  Definition of AE  ................................ ................................ ................................ ........... 101 
10.3.2.  Definition of SAE  ................................ ................................ ................................ ......... 102 
10.3.3.  Definition of Product Complaints  ................................ ................................ ................. 104 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ .................... 104 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ ........ 106 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............. 107 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ ........................ 108 
10.4.1.  Definitions ................................ ................................ ................................ ..................... 108 
10.4.2.  Contraception Guidance ................................ ................................ ................................ 109 
10.5.  Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................. 111 
10.6.  Appendix 6: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Pr ocedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ .......... 113 
10.7.  Appendix 7: Country -specific Requirements  ................................ ............................... 114 
10.7.1.  Canada ................................ ................................ ................................ ........................... 114 
10.7.2.  Brazil  ................................ ................................ ................................ ............................. 115 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
10 10.7.3.  Germany  ................................ ................................ ................................ ........................ 117 
10.8.  Appendix 8: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ........................... 122 
10.9.  Appendix 9: Abbreviations and Definitions  ................................ ................................ .126 
10.10.  Appendi x 10: Protocol Amendment History  ................................ ................................ 130 
11. References  ................................ ................................ ................................ .................... 132 
 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
11 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  
A Phase 3, Parallel -Design, Open -Label, Randomized Control Study to Evaluate the Efficacy 
and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin 
Naïve Adults with Type 2 Diabetes  
Brief Title:  
Efficacy and Safety of LY3209590 Compared to Degludec in Adults with Type 2 Diabetes Who 
Are Starting Basal Insulin for the First Time 
Regulatory Agency Identifier Number(s):  
IND: 129390  
EudraCT: 2021 -005891 -21 
Rationale : 
This Phase 3 study will  evaluate the efficacy and safety of once -weekly administration of 
LY3209590  on glycemic control compared with daily administration  of insulin degludec in 
insulin naïve adult participants with Type 2 diabetes ( T2D) who are starting basal insulin therapy 
for the first time. This study will inform the clinical development of LY3209590.  
Objectives , Endpoint s, and Estimands:  
Objectives  Endpoints  
Primary  
Demonstrate noninferiority  of LY3209590 compared to 
insulin degludec for the treatment of T2D in adults  Change in HbA1c from baseline to Week 52  
Key Secondary (Multiplicity Adjusted)  
Demonstrate noninferiority of LY3209590 compared to 
insulin degludec for participants using GLP -1 receptor 
agonists  Change in HbA1c from baseline to Week 52  
Demonstrate noninferiority of LY3209590 compared to 
insulin degludec for participants not using GLP -1 
receptor agonists  Change in HbA1c from baseline to Week 52  
Demonstrate superiority of L Y3209590 compared to 
insulin degludec in selected parameters of glycemic 
control   Change in HbA1c from baseline to Week 52  
 Time in glucose range between 70 and 180  mg/dL 
(3.9 and 10.0 mmol/L) , inclusive, collected during 
the CGM session prior to  Week 52  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
12 Other Secondary  
Compare the effect of LY3209590 to insulin degludec 
in parameters of glycemic control   Change from baseline to Week 26 of HbA1c  
 Time in glucose range between 70 and 180  mg/dL  
(3.9 and 10.0 mmol/L) , inclusive, collected during 
the CGM session prior to Week 26  
 Change from baseline to Week 26 and Week 52 of 
fasting glucose measured by SMBG  
 Glucose variability measured during the CGM 
session prior to Week s 26 and 52  
 Insulin dose at Week s 26 and 52  
Compare the effect of LY3209590 to insulin deglud ec 
on safety endpoints   Incidence and rate of composite of Level 2 and 3 
hypoglycemia events during treatment period  
 Incidence and rate of composite of Level 2 and 3 
nocturnal hypoglycemia events during treatment 
period  
 Change from baseline to Week s 26 and 52 in body 
weight  
 Measurements collected during CGM sessions 
prior to Weeks 12, 26 , and 52 of  
o Time in hypoglycemia with glucose  
<70 mg/dL  (3.9 mmol/L)  
o Time in hypoglycemia with glucose  
<54 mg/dL  (3.0 mmol/L), and  
o Time in hyperglycemia defined as 
glucose >180  mg/dL (10.0 mmol/L)  
Compare the effect of LY3209590 to insulin degludec 
on patient -reported outcomes questionnaires   Change from baseline to Week s 26 and 52 of  
o TRIM -D 
o SF-36, and  
o EQ-5D-5L 
Abbreviations: CGM = continuous glucose monitoring; SF -36 = Sho rt Form -36; SMBG = self -monitoring of blood 
glucose; T2D = type 2 diabetes; TRIM -D = Treatment -Related Impact Measure – Diabetes.  
Overall Design  
This is a Phase 3, parallel -design, open -label, randomized control study to evaluate the efficacy 
and safety of  LY3209590 administered once -weekly compared to insulin degludec  administered 
daily , in insulin -naïve adults with T2D who are on stable treatment with 1 to 3 noninsulin 
diabetes medications prior to entering the study. Participants will continue prior stable therapy 
with 1 to 3 allowed noninsulin diabetes medications during the study.  
The study includes a 3-week screening and lead -in period,  a 52-week treatment period, and a 
safety follow -up period approximately 5 weeks after  the last visit in the treatment period.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
13 Brief Summary  
All participants will use a study -provided, blinded continuous -glucose monitoring (CGM) 
system, glucometer, and e -diary to facilitate diabetes and hypoglycemia managem ent and for 
data collection throughout the study.  
The primary outcome is the change in hemoglobin A1c (HbA1c) from baseline at Week 52. 
Study Population:  
In general, partici pants may take part in the study if they 
 are 18 years of age or older  
 have a diagnos is of T2D 
 are starting basal insulin for the first time  
 have been taking  1 to 3 medication  that lowers their blood glucose level s for at least 3 
months prior to screening  and are willing to maintain this stable treatment for the 
duration fo r the study , and  
 are reliable and willing to make themselves available for the duration of the study and are 
willing and able to follow study procedures as required . 
In general, participants may not  take part  in the study if they  
 have received these diabetes treatments within 30 days prior to screening  
o glinides  
o glimins  
o pramlintide, or  
o insulin or any insulin containing product.  
 are women who are pregnant, lactating , or breastfeeding , or 
 have a history or presence of an underlying disease,  or surgical, physical, or medical 
condition that, in the opinion of the investigator, would potentially affect participant 
safety within the study or interfere with the interpretation of data.  
Number of Participants:  
Approximately 888 participants will be  randomly assigned to LY3209590 and insulin degludec 
in a 1:1 ratio. With the assumption of 15% dropout at Week 52, approximately 377 and 377 
participants will complete 52 weeks of treatment on LY3209590 and insulin degludec, 
respectively.  
Intervention Groups and Duration : 
Participants who meet entry criteria will be randomly assigned in a 1:1 ratio to LY3209590 or 
insulin degludec basal insulin treatment. LY3209590 will be administered once weekly, and 
insulin degludec  will be administered once daily.  
The study treatment period duration is 52 weeks . 
Both LY3209590 and insulin degludec will be administered by subcutaneous injection.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
14 Ethical Considerations of Benefit  or Risk:  
Considering the data that are available to date  from previous clinical studies , and the measures taken 
to ensure the safety of  the participants in this study, the potential risks related with LY3209590 are 
justified by the anticipated benefits a participant with T2D  may experience in the study . 
Data Monitoring Committee: Yes 
 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
15 1.2. Schema  
 
Abbreviations: CGM = blinded continuous glucose monitoring;  V = visit.  
Note: During the safety follow -up period, CGM device will be worn for 4 weeks (52 to 56), but device return and data download will occur a week later (on 
Week 57).  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
16 1.3. Schedule of Activities  (SoA)  
Two tables describe the schedule of activities.  
Table 1 (Section 1.3.1 ) describes  procedures for Screening Visit 1, Lead -In Visit 2, and Treatment Visits 3  to 18. 
Table 2 (Section  1.3.2 ) describes Treatment Visits 1 9 to 31, Early Discontinuation, Unscheduled Visits, and the Safety Follow -Up 
Visit s 801 and  802. 
Screening  
Screening procedures may be conducted over 1 to 3 days . 
Telehealth visits  
Telehealth visits may be by telephone or other technology. Gr ay-shaded columns in the SoA tables represent telehealth visits.  
Unscheduled visits  
Unscheduled visits may occur as needed. The SoA reflects some of the procedures that may occur during these visits. Perform 
additional procedures per investigator ’s discretion.  
Fasting visits  
Participants should not eat or drink anything but water for a minimum of 8 hours before a fasting  visit.  
If a participant attends these visits in a non -fasting state, the sample s should be collected as non -fasting and this will not be considered 
a protocol  deviation . 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
17 1.3.1.   Screening Visit 1, Lead -In Visit 2, and Treatment Visits 3 -18 
Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
Informed consent  X                                The ICF must be signed before any 
protocol -specific tests  or procedures are 
performed. See Section 10.1.3  for 
additional details.  
Inclusion  or exclusion 
criteria, review and 
confirm  X X X                Confirm inclusion and  exclusion criteria 
prior to randomization and 
administration of first dose of study 
intervention.  
Demographics  X                                Includes ethnicity (where permissible), 
year of birth, sex, and race . 
Preexisting conditions 
and medical history, 
including relevant 
surgical history  X                               Collect all ongoing conditions  and 
relevant past surgical and medical 
history.  
Prespecified medical 
history (indication and 
history of interest)  X                                 
Prior treatments for 
indication  X                                 
Substance use  
such as recreational 
drugs, alcohol, caffeine, 
and tobacco use  X                                 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
18 Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
Concomitant 
medications  X X X X X X X X X X X X X X X X X X  
Advers e events (AEs)  X X X X X X X X X X X X X X X X X X AEs are any events that occur after 
signing the informed consent.  
Hypoglycemia events  X X X X X X X X X X X X X X X X X X Clinical assessment based on participant 
history and e -diary entries.  
Physic al Evaluation   
Height  X                                Participant should remove shoes.  
Weight  X X X X X   X   X    X     X   X   
Vital signs  X X X X X   X   X    X     X  X  Include blood pressure and pulse rate. 
Measure 3 times, using the same arm, 
after participant has been sitting at least 
5 min and before ECG tracing and 
collection of blood samples for 
laboratory testing. Additional vital signs 
may be measured  as necessary  at 
investigator ’s discretion . 
Physical examination  X                  Additional physical examinations may 
be completed as necessary at 
investigator ’s discretion . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
19 Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
12-lead E CG (local)  X                  Participants should be supine for 
approximately 5 to 10 min before ECG 
collections and remain supine but awake 
during the ECG collection.  
ECGs may be repeated at the 
investigator’s discretion at any visit.  
ECGs will be performed prior to 
collection of any blood samples.  
Blinded Continuous Glucose Monitoring   
Dispense CGM   X                 Dispense supplies as needed.  
CGM sensor insertion   X X        X        Participants will be required to replace 
the sensor at designated intervals per the 
investigator instruction . Additional 
unscheduled visits may be needed  for 
participants support . 
CGM device return and 
data download    X    X        X     
Participa nt Education   
Diabetes counseling, 
training , and education   X X                Includes SMBG, hypoglycemia (see 
Sections 5.3 and 8.3.6 ).  
After Visit 3, conduct as needed . 
e-diary, glucometer, and 
CGM training   X X                After Visit 3, conduct as needed.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
20 Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
Electronic Participant Diary and Blood Glucose Meter   
Dispense e -diary  and 
glucometer   X                 Dispense supplies as needed.  
Diary com pliance check    X X X X X X X X X X X X X X X X Review entries of BG, hypoglycemia 
events, and insulin dose. If participant is 
not compliant, study personnel will re -
educate the participant on study 
requirements for continued study 
participation.  
Paper Pat ient-Reported Outcomes   
Treatment -Related 
Impact Measure - 
Diabetes  
(TRIM -D)   X                 
Electroni c Patient -reported Outcomes   
SF-36 v2 acute    X                 
EQ-5D-5L   X                 
Laborator y Tests and Sample Collections   
Hematology  X  X            X     
Hemoglobi n A1c 
(HbA1c)  X  X  X  X        X  X   
Clinical chemistry  X  X            X     
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
21 Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
Glucose        X             
Lipid pan el   X            X     
Urinalysi s  X                   
Serum pre gnancy  X  X                Collect for WOCBP only . 
Urine pregnancy (local)    X                The result must be available prior to first 
dose of intervention.  
Perform additional pregnancy tests if a 
menstrual period is missed, if there is 
clinical suspicion of  pregnancy, or as 
required by local law or regulation.  
Follicle -stimulating 
hormone (FSH)  X                  Perform as needed to confirm 
postmenopausal status. Definition in  
Section 10.4. 
C-Peptide    X                 
eGFR (CKD -EPI)  X  X            X     
UACR  X  X            X     
Pharmacokinetic (PK) 
samples    X  X  X        X    Visit 3: collect sample at least 15 min 
after dosing.  
For all other visits, collect at any time 
during the visit.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
22 Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
Immunogen icity (ADA) 
samples    X  X  X        X    Visit 3: collect sample before dosing.  
If an immediate or nonimmediate 
systemic drug hypersensitivity reaction 
occurs, collect additional unscheduled 
sample s as detailed in Section 10.2.1 .  
Stored Samples   
Exploratory biomarker 
samples    X                Collect before dosing.  
Random ization and Dosing Related Activities   
Process visit using 
IWRS  X X X X X X X X X X X X X X X X X X  
Randomization using 
IWRS      X                             
Insuli n dose assessment  
or adjustment  or 
documentation    X X X X X X X X X X X X X X X X  
Dispense LY3209590 or 
insulin degludec, and 
related supplies    X    X    X    X  X   
Site admi nisters 
LY3209590 or insulin 
degludec    X                 
Dosing an d injection 
training    X                After Visit 3, conduct as needed.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
23 Study  
I8H-MC-BDCX  
Table 1  Screening 
and 
Lead -In Treatment  Comments  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
Weeks from 
Randomization  -3 -2 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 18  
Visit Interval 
Tolerance (days)   ±3 — ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3  
Visit Detail    F   T F T  T  T T T F T  T T = telehealth visit  
F = fasting visit  
Observe participant 
administer LY3209590 
and insulin degludec     X                
Assess do sing 
compliance     X X X X X X X X X X X X X X X  
Participa nt returns 
unused LY3209590 or 
insulin degludec        X    X    X  X   
Abbreviations: ADA = antidrug antibody; BG = blood glucose ; CGM = continuous glucose monitoring; eGFR (CKD -EPI) = estimated glomerular filtration rate 
(chronic kidney disease epidemiology collaboration); ECG = electrocardiogram; FSH = follicle -stimulating hormone; ICF = informed consent form; IWRS = 
interactive web -response system; SF -36 v2 acute = Short Form -36 Version 2 Health Survey Acute Form; SMBG = self -monitoring of bloo d glucose; TRIM -D 
= Treatment -Related Impact Measure – Diabetes; UACR = urinary albumin/creatinine ratio; WOCBP = Women of childbearing potential.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
24 1.3.2.  Treatment Visits 1 9 to 31, Early Discontinuation, Unscheduled Visits, and Safety Follow -Up Visits 801 and 8 02 
Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
Concomitant medications  X X X X X X X X X X X X X X X X X  
Adverse events (AEs)  X X X X X X X X X X X X X X X X X See Section 10.3, 
Appendix 3 . 
Hypoglycemia events  X X X X X X X X X X X X X X X X X Clinical assessment based 
on participant history and 
e-diary entries.  
Physical Evaluation   
Weight   X    X   X  X  X X   X  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
25 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
Vital signs   X    X   X  X  X X   X Include blood pressure 
and pulse rate. Measure 3 
times, using the same 
arm, after participant has 
been sitting at least 5 min 
and before ECG tracing 
and collection of blood 
samples for labor atory 
testing. Additional vital 
signs may be measured as 
necessary at 
investigator ’s discretion.  
Physical examination       X       X X   X Additional physical 
examinations may be 
completed as necessary at 
investigator ’s discretion.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
26 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
12-lead ECG (local)              X X    Participants should be 
supine for approximately 
5 to 10 min before ECG 
collections and remain 
supine but awake during 
the ECG collection.  
ECGs may be repeated at 
the investigator’s 
discretion at any visit.  
ECGs will be performed 
prior to collection of any 
blood samples.  
Blinded Continuous Glucose Monitoring   
CGM sensor insertion   X         X  X     Participants will be 
required to replace the 
sensor at designated 
intervals per the 
investigator instruction . 
Additional unscheduled 
visits may be needed for 
participants support.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
27 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
CGM device return and data 
download       X       X X   X ED visit: if the ED visit 
occurs during a CGM 
session, the device must 
be return ed and data 
download ed.  
CGM device  will be worn 
for 4 weeks (52 to 56), 
but device return and data 
download  will occur a 
week later (on Week 57).  
Participant Education   
Diabetes counseling, 
training , and education                   Conduct as needed . 
e-diary, glucometer, and 
CGM training                   Conduct as needed . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
28 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
Electronic Participant Diary and Blood Glucose Meter   
Diary compliance check  X X X X X X X X X X X X X X X X X Review entries of BG, 
hypoglycemia events, and 
insulin dose. If participant 
is not compliant, study 
personnel will re -educate 
the participant on study 
requirements for 
continued study 
participation.  
Dispense ancillary supplies   X    X   X  X       Dispense supplies as 
needed.  
Required diary return               X   X The diary must  be 
return ed on the last 
participant visit.   
Electronic Patient -Reported Outcomes   
Simplicity Questionnaire 
(SIM -Q) study intervention       X       X X     
SF-36 v2® Health Survey       X       X X     
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
29 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
Basal Insulin Experience  
Likelihood of incorporating 
into routine              X X     
EQ-5D-5L      X       X X     
Paper Patient -Reported Outcomes   
Treatment -Related Impact 
Measure - Diabetes  
(TRIM -D)      X       X X     
Laboratory Tests and Sample Collections   
Hematology       X       X X   X  
Hemoglobin  A1c (HbA1c)       X   X    X X   X  
Clinical chemistry       X       X X   X  
Glucose          X          
Lipid panel       X       X X   X  
Urinalysis       X       X X   X  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
30 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
Urine pregnancy (local)               X   X Perform additional 
pregnancy tests if a 
menstrual period is 
missed, if there is clinical 
suspicion of pregnancy, 
or as required by local 
law or regulation.  
C-Peptide       X       X X     
eGFR (CKD -EPI)       X       X X   X  
UACR       X       X X   X  
Pharmacokinetic (PK) 
samples       X       X X   X Collect sample at any 
time during the visit.  
Immunogenicity (ADA) 
samples       X       X X   X If an immediate or 
nonimmediate systemic 
drug hypersensitivity 
reaction occurs, collect 
additional unscheduled 
sample s as detailed in 
Section 10.2.1 .  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
31 Study  
I8H-MC-BDCX  
Table 2  Treatment    Safety Follow -
Up Comments  
Visit Number  19 20 21 22 23 24 25 26 27 28 29 30 31 ED UV 801 802 ED = early 
discontinuation  
UV = unscheduled visit  
801, 802  = safety follow -
up 
Weeks from 
Randomization  20 22 23 24 25 26 28 32 36 42 48 50 52 — — 54 57  
Visit Interval Tolerance 
(days)  ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7 ±7 ±3 ±3 ±3 — — +7 ±7  
Visit Detail  T  T T T F T T F T  T F F  T F T = telehealth visit  
F = fasting visit  
Stored samples   
Exploratory biomarker 
samples              X X     
Dosing related activities   
Process visit using IWRS  X X X X X X X X X X X X X    X X  
Insulin dose assessment  or 
adjustment  or documentation  X X X X X X X X X X X X   X    
Dispense LY3209590  or 
insulin degludec, and related 
supplies   X    X   X  X        
Dosing and injection training                   After Visit 3, review 
conduct as needed.  
Assess dosing compliance  X X X X X X X X X X X X X X X    
 
Participant returns unused 
LY3209590 or insulin 
degludec   X    X   X  X  X X     
Assessment for post study  
treatment              X X  X X  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
32 Abbreviations: ADA = antidrug antibody; BG = blood glucose ; CGM = continuous glucose monitoring; eGFR (CKD -EPI) = estimated glomerular filtration rate 
(chronic kidney disease epidemiology collaboration); ECG = electrocardiogram; IWRS = interactive web -response system; SF -36 v2 acute = Short Form -36 
Version 2 Health Survey Acute Form; TRIM -D = Treatment -Related Impact Measure – Diabetes; UACR = urinary albumin/creatinine ratio; WOCBP = 
Women of childbearing potential.  
 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
33 2. Introduction  
LY3209590 is a long -acting insulin receptor agonist in development for the once -weekly 
treatment of hyperglycemia in patients with T2D and T1D.  
2.1. Study Rationale  
This Phase 3 study will  evaluate the efficacy and safety of once -weekly administration of 
LY3209590  on glycemic control compared with daily administration  of insulin degludec in 
insulin naïve adult participants with T2D  who are starting basal insulin therapy for the first time . 
This study will inform the clinical development of LY3209590 . 
2.2. Backg round  
Current state of diabetes care   
Most people with diabetes are not achieving glycemic targets. Treatment complexity, fear of 
hypoglycemia, delays in insulin initiation and intensification, and suboptimal dosing may pose 
challenges to diabetes care. There is a need to overcome barriers to dose optimization with basal 
insulins that provide simple dosing algorithms, rapid achievement of glycemic targets, and a 
predictable profile with low likelihood of contributing to hypoglycemia.  
Potential for improved treatment regimen s and compliance  
Once -weekly insulin with a simple titration regimen could result in earlier adoption of insulin 
therapy that may improve treatment compliance and lead to better real -world patient outcomes. 
Weekly insulins with a lower pea k-to-trough profile during the week and a nearly flat insulin 
profile could also reduce within -day glucose variability and result in more consistent and 
predictable glycemic control.  
LY3209590   
LY3209590 is a novel insulin receptor agonist that is in devel opment as a once -weekly basal 
insulin for the treatment of hyperglycemia in patients with T2D and T1D.  LY3209590 has the 
potential to decrease patient burden, overcome barriers to initiation of insulin therapy, and  may 
improve glycemic control and quality of life for these patients.  
A detailed description of the chemistry, pharmacology, non clinical  and clinical efficacy, and 
safety of LY3209590 is provided in the IB. 
Summary of c linical results  
A total of 5 clinical  studies , in healthy participants and participants with T2D , have been 
completed to assess the PK/PD, safety, and efficacy of LY3209590.  The results thus far support 
continued development of LY3209590 as a treatment for diabetes mellitus.  
Phase 1 results  
LY3209590 pharmacokinetics show a low p eak-to-trough ratio and extended half -life that 
supports once -weekly dosing.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
34 Single -ascending doses of LY3209590  lowered fasting glucose in a dose - and concentration -
dependent manner , with a prolonged time -action profile . 
Overall, LY3209590 was well tolerated in healthy participants and participants with T2D.  
Phase 2 Study BDCL preliminary results  
Study BDCL is a randomized, open -label, comparator -controlled study evaluating the efficacy 
and safety of LY3209590 compared with insulin degludec . Study p articipants have  T2D, are 
insulin naïve, and  treated with a stable dose of metformin, alone or in combination with a stable 
dose of a DPP -4 inhibitor a nd/or an SGLT2 inhibitor , for at least 3 months prior to screening.  
Safety data during 26 weeks of treatm ent in participants with T2D showed no increased risk of 
safety with LY3209590 compared to degludec.  
LY3209590 was noninferior to degludec for glycemic control as measured by change in HbA1c 
after 26 weeks of treatment.  
2.3. Benefit/Risk Assessment  
Detailed information about the known and expected benefits and risks and reasonably expected  
adverse events of LY3209590 may be found in the  IB, and that  of insulin degludec may be found 
in the  local product p ackage insert . 
2.3.1.  Risk Assessment  
Potential risks  for this study  
The potential risks associated with LY3209590 include  
 hypoglycemia  
 hyperglycemia  
 hypersensitivity  reaction  
 injection site reactions , for example, injection site rash, erythema, or pruritus or 
lipohypertrophy  
 immunogenicity, and  
 cardiovascular  risks.  
It is expected that the known risks would be similar to other insulin s. 
Safety data available to date suggest that there is no increased risk to participants’ safety with 
LY3209590 treatment compared to insulin degludec . 
Potential risks for the LY3 209590 -prefilled pen device are described in the “Instructions for 
Use”.  
Management of Risks  
Sections 5.1, 5.2, 6.1.2 , 6.8.1 , and 8.3 address known potential risks associated with LY3209590.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
35 Protocol risk m anagement  measures  
Participant education  for hypoglycemia  
After signing informed consent, a ll participants will be educated about signs and symptoms of 
hypoglycemia, how to treat hypoglycemia, and how to collect appropriate information for each 
episode of hypoglycemia. Hypoglycemia may be identified by spontaneous reporting of 
symptoms from participants, whether confirmed or unconfirmed by sim ultaneous glucose values , 
or by blood glucose samples collected between study visi ts. 
Monitoring of participant blood glucose levels  
Each participant will have a study -provided glucometer that will wirelessly transfer participant 
SMBG to the ir study -provid ed e-diary. Participants should use the glucometer  whenever 
hypoglycemia is experienced or suspected and check glucose value s. 
A web -interface and reporting system will be available for use by s tudy personnel to view 
participant e -diary  entries , including SMBG, insulin doses, and hypoglycemia information 
throughout the study. Automated alerts will be transmitted to the investigator any time the 
participant reports a potential severe episode of hypoglycemia , defined as  requiring assistance due 
to neurologica l impairment , in the e -diary.  
Dose modification  and rescue therapy  
The dosing algorithm used in the study requires consideration and adjustment of insulin dosing 
by the investigator based on participant FBG and hypoglycemia events  (see Section 6.5). 
Participants will be monitored for persistent, severe hyperglycemia and will receive rescue 
therapy  if this should occur ( see Section 6.1.2 ). 
2.3.2.  Benefit Assessment  
Participants may benefit  by receiving  personal health information , routine  safety assessments, 
and frequent engagement with  health care providers during the study , which provide 
opportunities for coaching and support . 
Participants may also benefit  from the improvement of glycemic control promoted by basal 
insulin . The weekly administration  of LY3209590  has the potential to off er a more consistent 
glycemic control . 
2.3.3.  Overall Benefit Risk Conclusion  
Considering the clinical data to date and measures taken to minimize risk for the participants in this 
study, the potential risks identified in association with LY3209590 are justified by the anticipated 
benefits that may be afforded to insulin naïve participants with T2D. 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
36 3. Objectives , Endpoints , and Estimands  
Objectives  Endpoints  
Primary  
Demonstrate noninferiority of LY3209590 compared to 
insulin degludec for the treatment of T2D in adults  Change in HbA1c from baseline to Week 52  
Key Secondary (Multiplicity Adjusted)  
Demonstrate noninferiority of LY3209590 compared to 
insulin degludec for participants using  GLP -1 receptor 
agonists  Change in HbA1c from baseline to Week 52  
Demonstrate noninferiority of LY3209590 compared to 
insulin degludec for participants not using GLP -1 
receptor agonists  Change in HbA1c from baseline to Week 52  
Demonstrate superiority of LY3209590 compared to 
insulin degludec  in selected parameters of gl ycemic 
control   Change in HbA1c from baseline to Week 52  
 Time in glucose range between 70 and 180  mg/dL  
(3.9 and 10.0 mmol/L ), inclusive, collected during 
the CGM session prior to  Week 52  
Other Secondary  
Compare the effect of LY3209590 to insulin degludec  
in parameters of glycemic control   Change from baseline to Week 26 of HbA1c  
 Time in glucose  range between 70 and 180  mg/dL  
(3.9 and 10.0 mmol/L) , inclusive,  collected during 
the CGM session prior to Week 26  
 Change from baseline to Week s 26 and 52 of 
fastin g glucose measured by SMBG  
 Glucose variability measured during the  CGM 
session prior to Week s 26 and 52  
 Insulin dose  at Week s 26 and 52  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
37 Compare the effect of LY3209590 to insulin degludec 
on safety endpoints   Incidence and rate of composite of Level 2 and 3 
hypoglycemia events during the treatment period  
 Incidence and rate of composite of Level 2 and 3 
nocturnal hypoglycemia events during the 
treatment period  
 Change from baseline to Week s 26 and 52 in body 
weight  
 Measure ments  collected  during CGM sessions 
prior to  Weeks 12, 26 , and 52 of  
o Time in hypoglycemia with glucose  
<70 mg/dL  (3.9 mmol/L ) 
o Time in hypoglycemia with glucose  
<54 mg/dL  (3.0 mmol/L)  
o Time in hyperglycemia defined as 
glucose >180  mg/dL  (10.0 mmol/L ) 
Compare the effect of LY3209590 to insul in degludec 
on patient -reported outcomes questionnaires   Change from baseline to Week s 26 and 52 of  
o TRIM -D 
o SF-36, and  
o EQ-5D-5L 
Tertiary  
Compare the effect of LY3209590 to insulin degludec  
in participants using  GLP -1 receptor agonists  versus 
participants not using  GLP -1 receptor agonists   Rate of Level 1 and composite of Level 2 and 3 
hypoglycemia events during the treatment period  
 Change from baseline to Week s 26 and 52 in body 
weight  
 Insulin dose at Week s 26 and 52  
 Measurements collected d uring CGM sessio ns 
prior to Weeks 12, 26 , and 52 of  
o Time in hypoglycemia with glucose  
<70 mg/dL  (3.9 mmol/L ) 
o Time in hypoglycemia with glucose  
<54 mg/dL  (3.0 mmol /L) 
o Time in hyperglycemia defined as 
glucose >180  mg/dL  (10.0 mmol/L ), and  
o Time in glucose range between 70 and 
180 mg/dL  (3.9 and 10.0 mmol/L) , 
inclusive  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
38 Compare the effect of LY3209590 to insulin degludec 
for efficacy parameters   Percentage of participants at Week 52 achieving  
o HbA1c <7%  
o HbA1c <7% without nocturnal 
hypoglycemia , and  
o HbA1c ≤6.5% without hypoglycemia  
 Change from baseline to Weeks 26 and 52 of 
fasting serum glucose  
Compare the effect of LY3209590 to insulin degludec 
for safety parameters   Incidence and rate of Level 2 hypoglycemia events 
during treatment period  
 Incidence and rate of Level 3  hypoglycemia events 
during treatment period  
 Evaluation of immunogenicity - incidence of 
positive LY3209590 treatment -emergent antidrug 
antibodies  
Characterize the PK/PD  of LY3209590   LY3209590 PK and concentration -response 
relationships to key safety and efficacy measures  
Compare the effect of LY3209590 to insulin degludec 
for patient -reported outcomes   SIM-Q and 
 Frequency of responses to Basal Insulin 
Experience of “likelihood of incorporating into 
routine”  
Abbreviations: CGM = continuous glucose monitor ing; GLP -1 = glucagon -like peptide -1; HbA1c = hemoglobin 
A1c; PK/PD = pharmacokinetics/pharmacodynamics; SMBG = self -monitoring of blood glucose; SF-36 = Short 
Form-36 Version 2  Health Survey Acute Form; SIM-Q = Simplicity Questionnaire; T2D = type 2 diabetes; 
TRIM -D = Treatment -Related Impact Measure – Diabetes . 
Primary estimand  
United States registration  
The primary clinical question of interest is  
What is the treatment difference between LY3209590 and insulin degludec in HbA1c 
change from baseline  after 52 weeks of treatment , in study eligible participants , 
regardless of treatment discontinuation for any reason and regardless of initiation of 
rescue medication?  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
39 Treatment regimen  estimand attributes  
This table describes the treatment regimen  estimand attributes.  
Treatment Regimen  Estimand Attribute  Description  
Population  Targeted study population . See Section 9.2 for details.  
Endpoint  HbA1c c hange from baseline to Week 52 . 
Remaining intercurrent events  None. The 2 intercurrent events, treatment 
discontinuation for any reason and initiation of rescue 
medication, are both addressed by the treatment 
condition of interest attribute . 
Treatment condition  The randomized treatment regardless of treatment 
discontinuation and use of rescue medications . 
Population -level summary  Difference in mean change s between treatment 
conditions . 
Rationale for the treatment regimen estimand  
The treatment regimen estimand estimates how participants with T2D are treated in clinical 
practice and considers both efficacy and safety.  
Registration for countries  outside the United States  
The primary clinical questio n of interest is  
What is the treatment difference between LY3209590 and insulin degludec in HbA1c 
change from baseline after 52 weeks of treatment, in study eligible participants  who 
adhere to the randomized treatment without intercurrent events during the  study treatment 
period ? 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
40 Efficacy  estimand attributes  
This table describes the efficacy  estimand attributes.  
Efficacy Regimen Estimand Attribute  Description  
Population  Targeted study population . See Section 9.2 for details.  
Endpoint  HbA1c c hange from baseline to Week 52.  
Remaining intercurrent events  None. The 2 intercurrent events, treatment 
discontinuation for any reason and initiation of rescu e 
medication, are both handled by the hypothetical 
strategy, for example, the potential outcome  for those 
participants if the intercurrent events have not occurred 
will be estimated.  
Treatment condition  The randomized treatment.  
Population -level summary   Difference in mean change s between treatment 
conditions.  
Rationale for the efficacy estimand  
The efficacy estimand supports the interpretation of the treatment effect as participants adhere to 
study treatment and free from the confounding effect of rescue medications.  
Secondary estimands  for multiplicity -adjusted objectives  
The superiority test in change from baseline to Visit 31 (Week 52) in HbA1c will also be based 
on the primary estimands described above.  
The change from baseline to Visit 31 (Week  52) in HbA1c  in the subpopulations of participants 
using  or not using  GLP -1 receptor agonists will use treatment regimen estima nd for US 
registration and efficacy estimand for other countries.  
The time in glucose range between 70 and 180  mg/dL  (3.9 and 1 0.0 mmol/L) inclusive measured 
during CGM session prior to Visit 31 (Week 52) will use treatment regimen estimated for US 
registration and efficacy estimand for other countries.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
41 4. Study Design  
4.1. Overall  Design  
This is a Phase  3, parallel -design, open -label, randomized control study to evaluate the efficacy 
and safety of LY3209590  administered once -weekly compared to insulin degludec  administered 
daily . 
The study includes a 3-week screening  and lead-in period,  a 52-week treatme nt period, and a 
safety follow -up period  approximately  5 weeks after the last visit in the treatment period . 
Screening and Lead -In 
Visit 1: Screening  
Interested participants will sign the appropriate informed consent document(s) prior to initiating 
any procedures.  
The investigator will review medical history, symptoms, risk factors, and other inclusion and 
exclusion criteria prior to any diagnostic  procedures. If the participant is eligible after this 
review, then the site will perform the diagnostic  procedures to confirm eligibility.  
Visit 2: Lead -In 
Participants will receive their e -diary, glucometer , and the CGM system.  
Participants will receive training on  
 diabetes self -monitoring and management  
 study glucometer  
 CGM  
 electronic study diaries, and  
 study  requirements.  
The CGM sensor will be inserted at Visit 2, and participants will be required to wear the sensor 
and insert a new sensor when indicated  per the SoA . 
Starting with Visit 2, participants must measure their FBG levels each day when possible or at a 
minimum 3 times per week.  
Participants will continue their current diabetes therapy until randomization.  
Treatment period  
Visit 3  (Week 0) : Randomization  
This is the general flow for Visit 3  
 study personnel confirm enrollment criteria  
 participants are  randomly assigned to an intervention group  
 study personnel c omplete baseline procedures and sample collection  
 study personnel will provide dosing training and administer the first dose of LY3209590 
or insulin degludec ,  
 study personnel will download the CGM  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
42  participant will continue CGM wear per the SoA, and  
 study personnel complete all visit procedures.  
Participants assigned to insulin degludec will continue daily administration after Visit 3.  
Visit 4  (Week 1)  
Study personnel and p articipants complete a ll visit procedures described in the SoA.  
Study personnel will provide dosing training  and observe p articipants administer their second 
dose of LY3209590 , or insulin degludec . 
Visit  5 through  Visit 3 1 (Week  2 through Week 52)  
Study personnel and participants complete all visit procedures described in the SoA.  
The participant’s median FBG will be used to titrate basal insulin dose adjustments throughout 
the study based on the study titration algorithm described in Section 6.5.1 . 
Participants will collect blinded CGM for  
 4 weeks prior to Visit 7, and the site will download the CGM data at Visit 7  
 4 weeks prior to Visit 15, and the site will download the CGM data at Visit 15  
 4 weeks prior to Visit 2 4, and the site will download the CGM data at Visit 2 4; and 
 4 weeks prior to Visit 31, and the site will download the CGM data at Visit 31. 
The investigator or study staff will review participant e -diary compliance for  
 SMBG  
 hypoglycemia events , including related signs and symptoms , and  
 dosing  information,  including date and time of doses. 
Last study treatment visit : either Visit 3 1 (Week 52) or ED visit  
Participants should complete all visit procedures  in a fasting state.  
Participants will return unused study intervention to the investigative site.  
Assessments for the transition to non-study diabetic treatment  after the participant’s last dose  
The investigator will determine a participant’s tr ansition  from study treatment to another non -
study diabetic treatment . 
Participants will continue their concomitant antihyperglycemic medications at the discretion of 
the investigator.  
Safety follow -up visits 801 and 802  
Study personnel and participants complete all visit procedures described in the SoA.  
Participants will collect blinded CGM for 4 weeks  following Visit 31 , and the site will download 
the CGM data at Visit 802.  
The investigator  will follow -up on the participant’s transition from study treat ment to another 
non-study diabetic treatment.  
Participants will return study devices at the final study visit.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
43 4.2. Scientific Rationale for Study Design  
Primary endpoint  
The primary efficacy measurement is HbA1c, a widely used measure of glycemic control that 
reflects a cumulative history of glucose levels in the preceding 2 to 3 months.  
Overall design  
Blinding  
This is an open -label study. Investigators, participants, and study -site personnel will be 
unblinded to the assigned treatment. To eliminate potential biases, designated members of the 
Lilly study team will remain blinded throughout the study (see Section 6.3). Only a minimum 
number of Lilly personnel will see the randomization table and treatment assignments before the 
study is complete.  
Study Duration  
The treatment duration of 52 weeks is a reasonable time  frame to observe  the effects of 
LY3209590  compared to insulin degludec.  
The follow -up visit after the last dose is designed to capture any additional safety signals  and to 
monitor the transition from study treatment to non -study diabetic treatment.  
Comparator  
Insulin degludec was chosen as the comparator because it is widely accepted as the best -in-class 
basal insulin.  
Collection of race and ethnicity data  
In this study, collection of demographic information includes ethnicity  (where permissible ) and 
race. The scientific rationale is based on the need to assess variable response in safety or efficacy 
based on race or ethnicity. This question can be answered only if all the relevant data are 
collected.  
4.3. Justification for Dose  
The dosing guidance for starting doses and dose titrations of LY3209590 and insulin degludec 
are derived based on findings from Phase 2 studies and model -based simulations. These data 
informed the development of a titration algorithm to safely and efficiently initiate and guide 
LY3209590 and insulin degludec dose adjustments to achieve the same glycemic goals of FBG 
between 80 and 120  mg/dL  (4.4 and 6.6 mmol/L) , while minimizing hypoglycemia risk.  
See Section 6.5 for dose modification and titration details.  
LY3209590  
Initial loading dose  
The initial loading dose aims to optimize and accelerate glycemic control by allowing 
participants to reach a steady -state concentration faster.  The use of a single one -time-only 
loading dose enables pa rticipan ts to achieve concentrations close to steady state within a few 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
44 days rather than a period of weeks. This approach minimizes the significant titrations while 
reaching steady state . 
Participants randomly assigned to LY3209590 will receive a single loading dose of 300  U of 
LY3209590, which equals 3 times the starting weekly  dose of 100  U. 
This approach is supp orted by the Phase 2 Study BDC L and PK model -based simulations.  
Starting weekly dose 
The second dose is the starting weekly  dose of 100  U, unless hypoglycemia is observed  after the 
initial loading dose , requiring a dose reduction . 
Dose Adjustments  
Assessments for dose adjustment  will occur from the third  dose onwards . Dosing will be 
individualized based on FBG and hypoglycemia events , and adjustments should occur weekly 
from Visit s 5 to 15 (Week s 2 to 12) and then every 4 weeks thereafter . 
Insulin degludec  
Insulin degludec will be titrated to achieve the FBG target using an algorithm that is patterned 
after the well -established Riddle algorithm but modified to balance efficacy and hypoglycemia 
risk for the same FBG targets as LY3209590.  
Starting dos e 
The starting dose is 10  U, consisten t with the insulin degludec label.  
Dose Adjustments  
Dosing will be individualized based on FBG and hypoglycemia events, and adjustments should 
occur weekly from Visits 4 to 15 (Weeks 1 to 12) and then every 4 weeks thereafter.  
4.4. End of Study  Definition  
The end of the study is defined as the date of the last scheduled procedure shown in the SoA for 
the last participant in the study . 
A participant is considered to have completed the study if the participant  has completed all 
periods  of the study including the last scheduled procedure shown in the SoA. 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
45 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following  criteria apply : 
Age 
1. Are ≥18 years of age inclusive, at screening , or older per local regulations . 
Type of Participant and Disease Characteristi cs 
2. Have a diagnosis of T2D according to the World Health Organization  criteria . 
3. Have an HbA 1c of 7.0% -10.5% , inclusive , as determined by central laboratory at 
screening . 
4. Are on a stable  treatment with 1 to 3 antihyperglycemic  medication , for at least 3 months 
prior to screening , and willing to continue the stable treatment for the duration of the 
study . Therapies must be used in accordance with the corresponding local product label.  
These antihyperglycemic  medications are accept ed in the study  
 DPP-4 inhibitors  
 SGLT2 inhibitors  
 biguanides, such as metformin  
 alpha-glucosidas e inhibitors  
 GLP -1 receptor agonists , oral or injectable  
 sulfonylureas , or 
  thiazoli dinediones . 
5. Are insulin naïve . 
Exception s: 
 short -term insulin treatment for a maxi mum of 14 days , prior to screening , and  
 prior insulin treatment for gestational diabetes . 
Weight  
6. Have a body mass index ≤45 kg/m2. 
Contraceptive  or barrier requirements  
Contraceptive use by participants should be consistent with local regulations regarding the 
methods of  contraception for those participating in clinical studies.  
7. Male participa nts: no male contraception required except in compliance with specific 
local government requirements . 
Female participants: for the contraception requirements of this protocol, see Se ction 10.4. 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
46 Study Procedures  
8. Are reliable and willing to make themselves available for the duration of the study and 
are willing and able to follow study procedures  as required, such as  
 self-inject intervention  
 store and t ake provided study intervention s as directed  
 maintain an electronic study diary  
 use only the glucometer supplied for use in the study , and  
 wear the CGM  device  as directed , see Sectio n 8.1.1.2 . 
Note: The use of personal, non -study CGM device will not be allowed . 
Note:  persons with physical limitations who are not able to perform the injections must 
have the assistance of  an individu al trained to inject the intervention.  
Informed Consent  
9. Are c apable of giving signed informed consent as described in Section 10.1.3 , which 
includes compliance with the requirements and restrictions listed in the ICF and in this 
protocol . 
Other Inclusions  
10. Have usual wake and sleep patterns, such that midnight to 0600 hours will reliably reflect 
a usual sleeping pattern.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following  criteria appl ies: 
Medical conditions  
11. Have a diagnosis of T1D , latent autoimmune diabetes, or specific type of diabetes other 
than T2D, for example, monogenic diabetes, diseases of the exocrine pancreas, or drug -
induced or chemical -induced diabetes.  
12. Have a history of >1 episode of ketoacidosis or hyperosmolar state or coma requiring 
hospitalization within 6 months prior to screening.  
13. Have had severe hypoglycemia episodes within 6 mon ths prior to screening.  
14. Have a history of renal transplantation, are currently receiving renal dialysis, or have an 
estimated glomerular filtration rate <20  mL/min/1.73  m2 as calculated by the Chronic 
Kidney Disease -Epidemiology equation , determined by cen tral lab oratory  at screening . 
15. Have had a blood transfusion or severe blood loss within 90 days prior to screening . 
16. Have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other 
traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c.  
17. Have had New York Heart Association Class IV heart failure or any of these 
cardiovascular conditions within 3 months prior to screening  
 acute myocardial infarction  
 cerebrovascular accident (stroke), or  
 coronary bypass surgery.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
47 18. Have had gastric bypass  (bariatric) surgery, restrictive bariatric surgery, for example Lap -
Band, or sleeve gastrectomy within 1 year prior to screening . 
19. Have had a significant weight gain or loss within 3 months prior to screening, for 
example, ≥5%. 
20. Have acute or chronic hepatitis, cirrhosis, or obvious clinical signs or symptoms of any 
other liver disease , except non-alcoholic fatty liver disease  (that is, study participants  
with non-alcoholic fatty liver disease  are eligible for participation),  and/or have elevated 
liver enzyme measurements , as determined by the central laboratory  at screening and as 
indicated below:  
a. Total bilirubin >2x ULN , with the  except ion of previously diagnosed  Gilbert’s 
disease  
b. ALT or serum glutamic pyruvic transaminase  >3x ULN  
c. AST  or serum glutamic oxaloacetic transaminase  >3x ULN, or  
d. ALP  >2.5x ULN.  
21. Have a history of an active or untreated malignancy  or are in  remission from a clinically 
significant malignancy  within 5 years prior to screening.  
Exceptions:  
 Basal cell or squamous cell skin cancer . 
22. Are at increased risk for developing cancer or a recurrence of cancer.  
23. Have a history of or current significant psychiatric disorders considered clinically 
significant, in the  opinion of the investigator.  
24. Have a history or presence of an underlying disease, or surgical, physical, or medical 
condition that, in the opinion of the investigator, would potentially affect participant 
safety within the study or interfere with the interpretation of data.  
25.  Have a known hypersensitivi ty or allergy to any of the study interventions or their 
excipients . 
Prior  or Concomitant Therapy  
26. Have received  these diabetes treatment s within 30 days prior to screening  
 glinides  
 glimins  
 pramlintide , or 
 insulin or any insulin containing product.  
27. Are receiving or received systemic glucocorticoid therapy  for >14 days within the month 
before  screening.  
Exceptions:  
 replacement therapy for adrenal insufficiency  
 topical, intraocular, intranasal, or inhaled preparations, or  
 intra-articular injection . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
48 Prior  or Concurrent Clinical Study Experience  
28. Are currently enrolled or have participated within the last 30 days  in a clinical study 
involving an investigational intervention or any other type of medical research judged not 
to be scientifically or medically co mpatible with this study.  If the previous investigational 
intervention has a long half -life, 3 months or 5 half -lives, whichever is longer, should  
have passed prior to Visit 1.  
29. Have previously completed or withdrawn from this study  after having signed the ICF or 
any other study investigating LY3209590  after receiving at least 1 dose of the study basal 
insulin . 
Other Exclusions  
30. Have hypoglycemia unawareness in the opinion of the investigator.  
31. Are women who test positive for pregnancy  or intend to become pregnant . 
32. Are women who are lactating or breastfeeding . 
33. Have evidence of any substance use disorder of any severity defined by the Diagnostic 
and Statistical Manual of Mental Disorders -5, within 6 months prior to screening.  
Exceptions:  nicotine or caffeine.  
34. Are Lilly employees or are employees of any third party involved in the study who 
require exclusion of their employees.  
35. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate fa mily is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.  
36. Are unsuitable for inclusion in the study in the opinion of the investigator.  
5.3. Lifestyle Considerations  
Diabetes management counseling  
Qualified study personnel  will provide diabetes management counseling, which will include 
instructions on diet and exercise and education about the signs, symptoms, and treatment of 
hypoglycemia, should it occur. Diabetes self -management counseling may be reviewed 
throughout the stu dy, as needed.  
Dietary and exercise considerations  
Study participants should generally follow a healthy meal plan and continue their usual exercise 
habits throughout the course of the study.  
Dietary and exercise restrictions  
Study participants should not initiate an intensive diet  or exercise program with the intent of 
reducing body weight at any time during the study, other than the lifestyle and dietary measures 
for diabetes treatment.  
Blood donation  
Study participants should not donate blood or blood pr oducts during the study or for 4 weeks 
following their last study visit.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
49 5.4. Screen Failures  
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently randomly assigned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participant s to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory author ities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any SAE . 
Individuals who do not meet the criteria for participation in this study (screen failure) will not be 
rescreened.  
5.5. Criteria for Temporarily Delaying Enrollment  of a Participant  
This section is not applicable to this study. All entry criteria must be met within the specified 
intervals in the SoA.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
50 6. Study Intervention (s) and Concomitant Therapy  
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to  or used by  a study participant 
according to the study protocol.  
Investigators and other study personnel are expected to treat participants according to the 
nationally established standards of care for diabetes management in respective participating 
countries, except where that treatment would be in conflict with the protocol -provided treatment 
requirements. If there are no local  or national standards of care f or diabetes, the investigators 
should follow current published standards of care from the American Diabetes Association . 
6.1. Study Intervention(s) Administered  
LY3209590 and insulin degludec  will be dispensed at the study visits summarized in SoA.  
Returned LY3209590 or insulin degludec  should not be re -dispensed to the participants.  
This table lists the interventions used in this clinical study.  
Intervention Name  LY3209590  Insulin d egludec  
IMP and NIMP/AxMP  IMP IMP 
Authorized as defined by 
EU Clinical Tria l 
Regulationa No Yes 
Use Experimental  Active  comparator  
Type  Biologic  Biologic  
Dose Formulation  Solution  Solution  
Unit Dose Strength(s)  500 units/mL  100 un its/mL  
Dosage Level(s)  Individualized dosing  
(see Section 6.5.1 ) Individualized dosing  
(see Section  6.5.2 ) 
Frequency of 
Administration  Once weekly  Once daily  
Route of Administration  Subcutaneous  Subcutaneous  
Abbreviations: AxMP = auxiliary medicinal product; IMP = Investigational Medicinal Product; NIMP = non -
investigational medicinal product.  
a Study interventions identified as authorized are used in accordance with the terms of their marketing 
authorizations.  
LY3209590 frequency of administration and guidance for missed doses  
LY3209590 should be administered once weekly at approximately the same time and day each 
week. If a dose is missed, it should be administered as soon as possible if at least 3 days (72 
hours) remain until the next scheduled dose. If less than 3 days remain before the n ext scheduled 
dose, skip the missed dose and administer the next dose on the regularly scheduled day.  
In each case, participants can then resume their regular once -weekly dosing schedule.  
The day of weekly administration can be changed, if necessary, only if the last dose has been 
administered at least 3 days earlier.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
51 Insulin degludec frequency of administration  
Insulin degludec should  be administered daily at approximately the same time each day . 
Anatomical Location of Injections  
For both LY3209590 and insulin degludec , participants should  rotate injection sites from one 
injection to the next, even when injecting within the same region.  Injections may be administered 
in the abdomen, thigh, arm, or buttock. Refer to the IFU for complete instructions on do se 
administration.  
Packaging and labeling  
Study interventions will be supplied by the sponsor or its designee  in accordance with current 
Good Manufacturing Practice. Study interventions will be labeled as appropriate for country 
requirements.  
6.1.1.  Medical Devices  
LY3209590 or insulin degludec will be provided as a solution in a p refilled pen injector  for the 
administration of either LY3209590 or insulin degludec.  
Instructions for device use are provided in the “Instructions for Use .” 
All Product Complaints , including malfunction, use error and inadequate label ing, shall be 
documented and reported by the investigator throughout the clinical investigation (see Section  
8.3.1 ) and appropriately managed by the sponsor.  
6.1.2.  Rescue Medicine  for Management of Severe or Persistent Hyperglycemia  
If a participant develops severe, persistent hyperglycemia after randomization, optimization  of 
concomitant antihyperglycemi c medication and/or the addition  of an allowed agent for rescue 
therapy should be considered after investigator assessment , based on conditions described in this 
table . 
Average of FBG over 2 -week period  Timing of events  
>270  mg/dL  (15 mmol/L)  From Visit 15 until 17 (Week 12 to 16)  
>240  mg/dL  (13 mmol/L)  After  Visit  17 until 19 (Week 16 to 20) 
>200  mg/dL  (11 mmol/L)  After  Visit 19 until 31 (Week 20 to end of study 
treatment at Week 52) 
First, investigators should  confirm participant  compliance with the assigned intervention and that 
they do not have an acute condition causing severe hyperglycemia.  
Rescue therapy will begin  with dose optimization  of the participant ’s current concomitant 
antihyperglycemic medications . Then  consider the addition of a n allowed agent for rescue 
therapy  (see Section 6.8.3 ), if applicable , so the participant is taking  up to 3 antihyperglycemi c 
medications at effective doses before considering prandial insulin rescue therapy . 
If severe, persistent hyperglycemia is not improving in spite of compliance with the assigned 
therapeutic regimen and optimization of other  concomitant glucose -lowering agents, the addition 
of prandial insulin may be considered.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
52 Participants who receive rescue therapy for hyperglycemia management should also continue 
administering  either LY3209590 or insulin degludec for the remaining period in the study.  
Participants who  require a non -study basal insulin or insulin mixture as rescue therapy must 
discontinue study basal insulin therapy (LY3209590 or insulin degludec). The participant will 
remain in the study and follow procedures for the remaining study visits . 
The investi gator should ensure that the participant met the criteria for severe or persistent 
hyperglycemia before initiating rescue medicine and document this in the source files.  
6.2. Preparation , Handling , Storage , and Accountability  
The investigator or designee must c onfirm appropriate storage conditions have been maintained 
during transit for all study intervention received and any discrepancies are reported and resolved 
before use of the study intervention.  
Only participants enrolled in the study may receive study in tervention . Only authorized study 
personnel  may supply , prepare,  or administer study intervention. All study intervention must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storag e conditions with access limited to the investigator and 
authorized  study personnel . 
The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, reconciliation, and final 
disposition records).  
Further guidance and information for the final disposition of unused study interventions are 
provided in the Pharmacy  Manual . 
Participant responsibilities  
In-use storage conditions are expected to  be followed  according to the instructions for use 
provided by the sponsor. Study participants will be trained on the proper storage and handling of 
the study intervention.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
Randomization and stratification  
All part icipants will be centrally assigned to randomized study intervention using an IWRS. 
Before the study is initiated, the login information and directions for the IWRS will be provided 
to each site.  
Participants will be randomly assigned in an 1:1 ratio to LY3209590:  insulin degludec.  
Participants will be stratified based on  
 country  
 HbA1c  stratum at Visit 1  (<8% and ≥8% )  
 sulfonylurea use at randomization  (Yes/No) , and 
 GLP -1 RA  use at randomization , regardless of oral or injectable administration  (Yes/No) . 
Blinding  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
53 This is an open -label study. Investigators and participants will be unblinded to the assigned 
treatment groups.  
The Lilly study team members who are closely involved in data interpretation and analysis 
planning will remain blinded throughout the course of the  study. O nly a minimum number of 
Lilly personnel will see the randomization table and treatment assignments before the study is 
complete.  
The investigator should make every effort to preserve the blinding  when contacting the Lil ly 
study team members, including the Lilly clinical research physician or scientist.  
Unblinded reviews  
External c ommittees reviewing unblinded data during the study are described in Section 10.1.5 . 
An early PK/PD unblinded transfer may also be conducted. Only a small group of personnel can be 
unblinded to the data for the potential PK/PD analysis and must keep information confidential until 
the planned  unblinding of the trial.  
6.4. Study Intervention Compliance  
Participants are responsible for  enter ing the date of their daily or weekly insulin dose and dose 
amount in their e -diary.  
The investigator or trained designee will assess treatment compliance at each  visit based on 
review of the participant glycemic control, e -diary completion, and adherence to prescribed dose 
and study procedures.  
If a participant  is considered poorly compliant with their study procedures , for example, missed 
visits or specific diagn ostic tests , they will be retrained as needed by designated s tudy personnel.  
6.5. Dose Modification  
Dosing will be individualized based on FBG and hypoglycemia events . The FBG target is 80  to 
120 mg/dL  (4.4 to 6.6 mmol/L) . 
The investigator  is responsible for titrating the basal insulin dose  using the guidance  in Section s 
6.5.1  and 6.5.2 . 
6.5.1.  LY3209590 Dose Initiation and Adjustment  
This section outlines the LY3209590  
 general dosing information by  visit 
 dose adjustment guidance based on FBG, and  
 dose adjustment guidance based on hypoglycemia.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
54 6.5.1.1.  LY3209590  General Dosing Information by Visit  
This table provides general dosing information across visits for all participants random ly 
assigned  to LY3209590.  
LY320959 0 General Dosing Information  
Visit  (Week) Dose  Additional dosing instruction  
Visit 3 (Week 0) initial loading 
dose  300 U  CAUTION:  Do NOT repeat 
administration of the loading dose .  
Visit 4 (Week 1) starting weekly 
dose  100 U If a participant experiences 
hypoglycemia in the previous week, 
then reduce the starting weekly 
dose to 60  U, a 40 U reduction  
based on adjustments for 
hypoglycemia ( see Section 6.5.1.3 ). 
Visits 5 -15 (Week s 2-12) Doses will be individualized based 
on FBG and hypoglycemia events  Dose modifications may occur 
weekly . 
After Visit 15  Doses will be individualized based 
on FBG and  hypoglycemia events  Dose modifications may occur 
every 4 weeks . 
6.5.1.2.  LY3209590 Dose Adjustment  Based on FBG  
This table provides guida nce for dose adjustments based on median FBG  from the 3 most 
recently recorded FBG data  from the previous week . 
If the participant experienced any documented BG ≤70  mg/dL (≤3.9 mmol/L) in the previous 
week, the dose should not be increased.  
If the median FBG is…  Then…  
mg/dL  mmol/L   
<80 <4.4 reduce  the LY3209590  dose by 2 0 U. 
80-120 4.4-6.6 do not change the dose . 
121-140 6.7-7.7 increase the LY3209590  dose by 20  U. 
>140  >7.7 increase the LY3209590  dose by 40  U. 
6.5.1.3.  LY3209590 Dose Adjustment B ased on Hypoglycemia Events  
This table provides guidance when hypoglycemia events occur . 
If a participant reports … with a blood  glucose value of ... 
over the previous week  then…  
≥3 hypoglycemic events  ≤70 mg/dL  (3.9 mmol/L)  
reduce the LY 3209590  dose by 40 U. ≥1 hypoglyc emic event  <54 mg/dL  (3.0 mmol/L)  
≥1 nocturnal  hypoglycemic event  ≤70 mg/dL  (3.9 mmol/L)  
Any confirmed severe 
hypoglycemia  
(neurological impairment confirmed 
by investigator)  ___ 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
55 6.5.2.  Insulin Degludec Dose Initiation and Adjustment  
This section outlines the insulin degludec  
 general dosing information by visit  
 dose adjustment guidance based on FBG, and  
 dose adjustment guidance based on hypoglycemia.  
6.5.2.1.  Insulin Degludec General Dosing Information by Visit  
This table provides general dosing information across visits for all participants randomized to 
insulin degludec.  
Insulin degludec General Dosing Information  
Visit  Dose  Additional dosing instruction  
Visit 3 (Week 0) starting dose  10 U/day   
Visits 4-15 (Week s 1-12) Doses will be individualized based 
on FBG and hypoglycemia events  Dose modifications may occur 
weekly  
After Visit 15  (Week 12) Doses will be individualized based 
on FBG and hypoglycemia events  Dose modifications may occur 
every 4 weeks  
6.5.2.2.  Insulin Degludec  Dose Adjustment Based on FBG  
This table provides guidance for dose adjustments based on median FBG from the 3 most 
recently recorded FBG data  from the previous week . 
If the participant experienced any documented hypoglycemia (BG  ≤70 mg/dL) (≤3.9 mmol/L)  in 
the previous week, the dose should not be increased.  
If the m edian FBG  is… Then…   
mg/dL  mmol/L   
<80 <4.4 reduc e the dose by 3 U. 
80-120 4.4-6.6 do not  change  the dose . 
121-140 6.7-7.7 increase the dose  by 3 U. 
>140 >7.7 increase the dose  by 6 U. 
6.5.2.3.  Insulin Degludec  Dose Adjustment Based on Hypoglycemia Events  
This table provides guidance when hypoglycemia events occur.  
If a participant reports…  with a blood glucose value of … 
over the previous week  then…  
≥3 hypoglycemic events  ≤70 mg/dL (≤3.9  mmol/L)  reduce the dose by 2  to 6 U. 
 
Dose reductions of 2 or 4 units 
may occur every 3 days to achieve 
a weekly 6  U reduction as 
clinically indicated  ≥1 hypoglycemic event  <54 mg/dL (3.0  mmol/L)  
≥1 nocturnal hypoglycemic event  ≤70 mg/dL (3.9  mmol/L)  
Any confirmed severe hypoglycemia  ___ 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
56 6.6. Continued Access to Study Intervention after the End of the Study  
The sponsor will not provide participants with any ongoing supplies of study intervention after 
they have completed the study treatment period or permanently discontinued the study 
intervention.  
6.7. Treatment of Overdose  
An overdose of LY3209590 or insulin degludec, defined as a dangerously large amount of 
insulin compared to the protocol -prescribed dose , will be reported as per Section 10.3.1 . In the 
event of an overdose, refer to the IB for LY3209590 or product label for insulin degludec 
depending on the participant treatment assignment.  
In the event of an overdose, the investigator  or treating physician should  
 contact the medica l monitor immediately  
 evaluate the participant to determine, in consultation with the medical 
monitor, whether study intervention should be interrupted or whether the dose 
should be reduced  
 consider holding sulfonylureas if clinically appropriate  
 closely m onitor the participant for any AE  or SAE and laboratory abnormalit y 
until study intervention no longer has a clinical effect, and  
 obtain a plasma sample for PK analysis if the participant is assigned to 
LY3209590 . 
6.8. Concomitant Therapy  
Concomitant therapy regimens  
All participants should maintain their usual medication regimens for concomitant conditions or 
diseases throughout the study, unless those medications are specifically excluded in the protocol  
(see Section 5.2). 
Participants taking concomitant medications should be on stable dosages at the time of screening 
and should remain at stable dosages throughout the study, unless changes need to be mad e 
because of an AE or rescue therapy  (see Section 6.1.2 ). 
Acceptable non -insulin diabetes treatment s are described in Section  6.8.3 . 
Changin g concomitant therapy  
Participants should consult with authorized study personnel before taking any new medications 
during the study , except when initiated for treatment of medic al emergencies . Authorized study 
personnel should consult the sponsor’s medical monitor if there are any questions about 
concomitant therapies during the study.  
Concomitant therapy data collection  
For therapy that the participant is receiving at the time of enrollment or receives during the 
study, including over -the-counter me dications, authorized study personnel should collect  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
57  the name of medication, vaccine , or therapy  
 the reason for use, and  
 dates of administration, including start and end dates.  
For diabetes and lipid -modifying medications, collect  dosage information includ ing dose and 
frequency.  
Non-study medicatio ns taken by study participants who have signed informed consent, but are not 
randomly assigned , will not be reported unless an SAE or AE occurs that the investigator believes 
may have been caused by a study proced ure. 
6.8.1.  Medications with Approved Weight Loss Indication  
Allowed usage of weight loss medication during the study  
A participant may use a medication that promotes weight loss if they are  on stable therapy 90 
days prior to screening.  
Allowe d medications include , but are not limited to  
 over-the-counter medications, including food supplements that promote weight loss  
 liraglutide 3.0  mg 
 orlistat  
 sibutramine  
 mazindol  
 phentermine  
 lorcaserin  
 phentermine  or topiramate combination  
 naltrexone  or bupropion , or 
 semaglutide injection 2.4  mg. 
Prohibited usage of weight loss medication during the study  
After screening, no prescription or over -the-counter medications that promote weight loss may 
be initiated or changes in dosage allowed.  
6.8.2.  Chronic Systemic Glucocorticoid  Medication  
Chronic systemic glucocorticoid therapy is allowed for no more than two 14-consecutive  day 
periods during study treatment period. Each period must be at least 30 days apart.  
This restriction does not apply to glucocorticoid therap y used as replacement therapy for adrenal 
insufficiency, or topical, intraocular, intranasal, inhaled preparations , and intra -articular  
injections . 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
58 6.8.3.  Antihyperglycemic Medications  
This table shows the conditions for use of  concomitant antihyperglycemi c medications . 
Drug Class  Use during Screening  or 
Lead -In Conditions for Use after Randomization  
 Y = yes, if on stable therapy 90 
days prior to screening.  
N = No During 
Treatment 
Period  Acute 
Therapy  
Treatment 
for up to 14 
days  Rescue 
Therapy  During 
Safety 
Follow -
Up 
Period  
GLP -1 RAs  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
DPP-4 inhibitors  Y N/A Y Y 
SGLT2 inhibitors  Y N/A Y Y 
Non-study basal 
insulins  N N Yes, only if 
study basal 
insulin is 
temporarily 
discontinued  See Note  Y 
Insulin mixtures  N N Yes, only if 
study basal 
insulin is 
discontinued  See Note  Y 
Prandial insulin  N N Y Y Y 
Meglitinides  N N N/A N Y 
Alpha -glucosidase 
inhibitors  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
Sulfonylureas  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
Thiazolidinediones  Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Y Y 
Metformin a Y Yes, if on 
stable therapy 
90 days prior 
to screening  N/A Yes, if the 
dose is below 
maximum 
approved dose 
per country -
specific label  Y 
Abbreviations: DPP -4 = dipeptidyl peptidase -4; GLP -1 RA = glucagon -like peptide -1 receptor agonist; N = no;  N/A 
= not applicable; SGLT2 = sodium -glucose cotransporter 2; Y = yes. 
a Switching metformin manufacturer is allowed if the dosage is the same. Changing to a metformin formulation 
with a different action profile (that is, from short -acting to long -acting metformin) is not permitted.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
59 Note: Participants who require a non -study basal insulin or insulin mixture as rescue therap y must discontinue study 
basal insulin therapy (LY3209590 or insulin degludec). The participant will remain in the study and follow 
procedures for the remaining study visits  
Dose adjustments of allowable non-insulin antihyperglycemic medications  are permit ted after 
randomization under the following circumstances : 
 situations that require short -term treatment interruption consistent with the product 
labeling for each respective country  
 situations that require dose adjustment or discontinuation per country -specific label, for 
example, in the case of reduced estimated glomerular filtration rate  
 in the case of increased hypoglycemia risk during the treatment period (as described in 
Section 8.3.6 ) 
 a dose increases as part of rescue therapy, and  
 for safety reasons at the discretion of the investigator.  
Any changes in dose should be documented.  
6.8.4.  Treatment after Study Completion  
Study interventions will not be made available to study participants after Visit 31 (Week 52) or 
after the participant’s early discontinuation from study treatment.  
At the last treatment visit (Visit 31 [Week 52] or E D visit), the investigator will determine 
participant’s transition from study treatment to another non -study diabetic treatment.  The 
investigator may prescribe a non -study basal insulin for use during the safety follow -up period. 
Participants will continue their concomitant non -insulin  antihyperglycemic medications at the 
discretion of the investigator and continue to monitor their FBG and complete the e -diary.  
Study participants treated with LY3209590  transitionin g to a non -study basal insulin : 
Study participants will receive the last in jection of LY3209590 at Week 52 of the study and can 
begin the transition to the non -study insulin after Visit 31 (Week 52). At Visit 31 (Week 52), the 
investigator will review the instructions for transitioning to the non -study insulin. During this 
transi tion period, the participant’s FBG should be used to guide dose initiation and adjustment 
for the insulin prescribed for the safety follow -up period.  
No daily basal insulin will be required until the FBG is above 120  mg/dL  (6.6 mmol/L)  for 2 
consecutive measurements. The prescribed non -study daily basal insulin should be started at a 
dose of 10 units/day and adjusted based on FBG and the investigator judgement in accordance 
with any country -specific label. The initial prescribed dose an d any d ose adjustments made for 
the non -study insulin during the safety follow -up period should be documented in the eCRF. An 
unscheduled visit in addition to Visit 801 may occur during this time to facilitate the transition to 
the non -study daily basal in sulin.  
Since LY3209590 has a half -life of approximately 17 days, a careful titration of the daily basal 
insulin is necessary to prevent hypoglycemia due to overlapping insulin action. Therefore, the 
investigator should consider titrating the daily insulin to reach 50% of the required daily dose at 
approximately 2 -weeks and 80% at approximately 4 -weeks.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
60 Study Participants treated with insulin degludec  transitioning to a non -study basal insulin : 
Study participants assigned to the insulin degludec treatment ar m may transition to a non -study  
basal insulin after Visit 31 (Week 52). The investigator will prescribe the non -study insulin and 
titrate the dose based on FBG  and clinical judgement in accordance with the country -specific 
label for the basal insulin. The initial prescribed  dose and any dose adjustments made during the 
safety follow -up period will be documented in the eCRF.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
61 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the study as a  whole are handled as part of Appendix 1.  
7.1. Discontinuation of Study Intervention  
When  necessary , a participant may be permanently discontinue d from  study intervention. If so, 
the participant will remain in the study and follow  procedures for remaining study  visits , as 
shown in the SoA . 
Participants who stop the study intervention permanently may receive another glucose -lowering 
medication. The new glucose -lowering medication will be recorded on the CRF for 
antihyperglycemic medications.  
A participant should be permanently discontinued  from study intervention if  
 the participant becomes pregnant during the study  
 the participant requests to discontinue study intervention  
 the participant  is diagnosed with an active or untreated malignancy , except for 
successfully  treated basal or squamous cell carcinoma  
 the participant did not take ins ulin degludec for more than 21 consecutive days or 
missed more than 3 consecutive doses of LY3209590 at any time during the study , or 
 in the opinion of the investigator, the participant should permanently discontinue the 
study intervention for safety reasons . 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
62 7.1.1.  Liver Chemistry Stopping Criteria  
The study intervention should be interrupted or discontinued if 1 or more of these conditions 
occur.  
Elevation  Exception  
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than 2 weeks   
ALT or AST >3x ULN and either TBL >2x ULN or INR >1.5  In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for intervention interruption or 
discontinuation decisions rath er than TBL 
>2x ULN.  
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3x ULN, when the source of increased ALP is the liver   
ALP >2.5x ULN and TBL >2x ULN  In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for intervention interruption or 
discontinuation decisions rather than TBL 
>2x ULN.  
ALP >2.5x ULN with the appearance of fatigue, nausea, v omiting, 
right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)   
Resumption of the study intervention can be considered only in consultation with the 
Lilly -designated medical monitor and only if the liver test results return to ba seline and if a 
self-limited, non -intervention etiology is identified.  
7.1.2.  Hypersensitivity Reactions  
If the investigator determines that a systemic hypersensitivity reaction has occurred related to 
study intervention administration, the participant may be permanently discontinued  from the 
study intervention, and the sponsor’s designated medical monitor should be notified.  
If the investigator is uncertain about whether a systemic hypersensitivity reaction has occurred 
and whether discontinuation of study int ervention is warranted, the investigator may consult the 
sponsor.  
7.1.3.  Temporary Discontinuation  of Study Intervention  
Criteria for temporary discontinuation of LY3209590 or insulin degludec  
The investigator may temporarily interrupt study treatment, due to an AE, clinically significant 
laboratory value, hospital visits, travel , or shortage of study treatment supply.  
This will be allowed for up to 21 consecutive days for insulin degludec or 3 consecutive doses 
for LY3209590 at any time during the study . This inf ormation should be documented by the 
investigator.  
Guidance when temporary discontinuation of study intervention occurs  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
63 Every effort should be made by the investigator to maintain participant s in the study and to 
restart study intervention promptly, as soon as it is safe to do so.  
Participants will continue their study visits and follow -up according to the SoA.  
Participant s should resume the dose prescribed before the temporary dosing interruption at the 
discretion of the investigator.  
Recording temporar y discontinuation of study intervention  
The dates of study intervention interruption and restart must be documented in source documents 
and entered on the CRF . 
Participant  noncompliance should not be recorded as interruption of study intervention  on the 
CRF. 
7.2. Participant Discontinuation/ Withdrawal from the Study  
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study  
 at any time at the participant’s  own request  
 at the request of the participant’s  designee , for example, parents or legal 
guardian  
 at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
 if the participant is diagnosed with any type of diabetes mellitus other than 
T2D 
 if enrolled in any other clinical study involving an investigational product , or 
enrolled in any other type of medical research judged not to be scientifically 
or medically compatible with this study , and  
 if the participant , for any reason, requires treatment with a therapeutic agent 
that is prohibited by the protocol and has been demonstrated to be effective 
for treatment of the study indication . In this case , discontinuation from the 
study occurs prior to introduction of the new agent . 
At the time of discontinuing from the study, if possible,  the participant will complete  procedures 
for an early discontinuation visit and post treatment  follow -up, as shown in the SoA.  
If the participant has not already discontinued the study intervention, the participant will be 
permanently discontinued  from the study intervention at the time of the decision to discontinue 
the study.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . 
If a participant  withdraws from the study, the participant  may request destruction of any samples 
taken and not tested , and the investigator must document this in the site study records . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
64 7.3. Lost to Follow  up 
Participant s will be considered lost to follow -up if they repeatedly fail to return for scheduled 
visits and are unable to be contacted by the study site. Site personnel or designee are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwise un able to be followed up by the site.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
65 8. Study Assessments and Procedures  
Study procedures and their timing are summarized in the SoA.  
Immediate  safety concerns  should be discussed with the s ponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention . 
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct . 
All screening evaluations must be completed and reviewed to confirm that  potential participant s 
meet all eligibility criteria. The investigator will maintain a screening log to record details of all 
participant s screened and to confirm eligibility or rec ord reasons for sc reening failure, as 
applicable.  
8.1. Efficacy Assessments  
Efficacy will be measured by  
 HbA1c  
 fasting blood glucose  measured by SMBG  
 Level 2 and 3 nocturnal hypoglycemia  
 Level 2 and 3 hypoglycemia events  
 body weight  
 insulin dose  
 CGM measurements  
o time in range between 70 and 180  mg/dL  (3.9 and 10  mmol/L) , inclusive  
o glucose variability, and  
o time in hyperglycemia or hypoglycemia , and  
 patient -reported  outcomes questionnaires  
o TRIM -D 
o SIM-Q 
o SF-36 v2 Health Survey  
o Basal Insulin Experience, and 
o EQ-5D-5L. 
See Section 3 for specific efficacy endpoints.  
See Section 8.3.6  for information related to hypoglycemia  and hyperglycemia . 
8.1.1.  Glucose Monitoring  
Participants must  use only the study -provided glucometer  during the study.  
8.1.1.1.  Self-Monitoring of Blood Glucose (SMBG)  
Glucometer for participant use during the study  
Participants will receive a sponsor -approved glucometer and related testing supplies for use 
during the study.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
66 Site personnel will train the participant on correct use of the glucometer for self -monitoring 
blood glucose and reporting of hypoglycemia data  in the  e-diary . 
Participants should use the glucometer  
 whenever hypoglycemia is experienced or suspected  
 when there is awareness of  increased risk related to changes in dietary intake, physical 
activity, or inadvertent or atypical insulin dosing  
 to check for hyperglycemic events, or  
 as directed by the investigator . 
When to measure fasting blood glucose (FBG) during the study  
Site pers onnel will train the participant  to measure FBG daily when possible, and a minimum of 
3 times per week using the study -provided  glucometer.  
The FBG should be measured upon waking in the morning, prior to food or caloric beverage 
intake.  
Glucometer data tra nsfer  
The study -provided glucometer will wirelessly transmit blood glucose measurements to the 
participant’s e -diary. Site personnel will be able to view SMBG data that have been transmitted 
to the e -diary through a web -based portal as well as any reported  events of hypoglycemia.  
8.1.1.2.  Continuous Glucose Monitoring (CGM) Systems  
The study -provided  CGM system or alternative sponsor -approved  glucose monitoring device 
will be used in blinded mode during the study . 
The blinded CGM will not display the sensor glucose readings to the participant or investigator, 
and high and low glucose alerts will not be available to the participant.  
Participants are not allowed to use a personal, non -study CGM device during the study . 
Training and initiation  
Site personnel will dispense CGM supplies and initiate blinded CGM sessions at the times 
specified according to the SoA . Participants will be trained on the CGM system before use and 
will be required to replace the sensor at designated intervals per the in vestigator instruction.  
Participants are not allowed to connect the transmitter and/or sensor of the CGM  system to a 
personal smartphone, smartphone application, or other system . 
CGM data compliance  
At the end of each CGM session, participants will return the CGM system or used sensors to the 
site. Site personnel will upload the CGM data to a vendor -hosted online portal to view data 
capture compliance using the available reports and visualization tools. The compliance threshold  
of 80% for each session is de fined as the percentage of actual data versus expected data collected 
during a session. Site personnel will re -educate participants on CGM operation and requirements 
when session compliance is <80%.  
To minimize data loss, the CGM service vendor will review  site uploads and notify site users 
and/or site monitor  when sessions do not meet the compliance thresholds. CGM compliance 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
67 reports will also be provided to the Sponsor during the study for review and to determine if 
further mitigation is necessary . 
8.1.2.  Patient -Reported Outcomes  
The self -administered questionnaires will be translated into the native language of the region and 
administered at the site during the designated visits in the SoA . 
Order of administering the  questionnaires during the visi t 
If the  participant is not adversely affected by their fasting condition, t he questionnaires should be 
completed before the participant has discussed their medical condition or progress in the study 
with the investigator or study personnel . 
Preferred administrati on order of these questionnaires is 
1. TRIM -D 
2. SIM-Q 
3. SF-36 v2 Health Survey  Acute Form  
4. Basal Insulin Experience: Likelihood of incorporating into routine, and  
5. EQ-5D-5L. 
8.1.2.1.  Treatment -Related Impact Measure – Diabetes (TRIM -D) 
Description of TRIM -D 
The TRIM -D is a participant self -administered instrument, which assesses the impact of diabetes 
treatment on participants’ functioning and well -being across available diabetes treatments. 
Participants assess  their experience “over the past 2 weeks .” 
The TRIM -D assess es 5 domains of impact . 
Domain  Number of items per domain  
Treatment Burden  6 
Daily Life  5 
Diabetes Management  5 
Compliance  4 
Psychological Health  8 
Scoring  
Each of the 28 items is assessed on a 5 -point scale, where higher scores indicate a better health 
state.  
8.1.2.2.  Simplicity of Diabetes Treatment Questionnaire (SIM -Q) Single Medication 
Status Version  
Description of SIM -Q 
The SIM -Q is a brief 10 -item measure developed to assess the simplicity and complexity of 
treatment for T2D. This version of the instrument assesses the simplicity and complexity of a 
single medication. The participant responses should consider  only the assigned study  
intervention . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
68 In this study , only the last 2 questions of the SIM -Q will be completed  
 “How simp le or complex is your medication treatment for diabetes?” and  
 “Overall, how simple or complex is it to manage your diabetes, including medication, 
checking your blood glucose levels, diet, and any other aspects of diabetes treatment?”  
Scoring  
Each item is  scored on a 5 -point scale ranging from “Very complex ” to “Very simple. ” 
8.1.2.3.  Short Form -36 Version 2  Health Survey Acute  Form  
Description of SF -36 v2 
The SF -36 v2  Health Survey Acute form  is a pa rticipant self -administered  measure  designed to 
assess  these 8 domains  
 Physical Functioning  
 Role Physical  
 Bodily Pain 
 General Health  
 Vitality  
 Social Functioning  
 Role Emotional, and  
 Mental Health.  
The Physical Functioning domain assesses limitations due to  health  “now” while the remaining 
domains assess functioning “in the past week.”  Participants answer each item  using  Likert 3-
point, 5 -point, or 6 -point scales  for the responses . 
Scoring  
Each domain is scored individually , and information from these 8 domains is further aggregated 
into 2 health component summary scores , the Physical Component Summary and Mental 
Component Summary.  
Scoring of each domain and both summary scores are norm based and presented in the form of 
T-scores, with a mean of 50 and standard dev iation of 10 . 
Higher  scores indicate better levels of function and/or better health  (Maruish 2011).  
8.1.2.4.  Basal Insulin Experience: Likelihood of Incorporating into Routine  
Description of questionnaire  
The Basal Insulin Experience: Likelihood of incorporating in to routine is a self -report ed scale 
consisting of a single question to understand the participant’s likelihood of incorporating their 
study insulin into their diabetes management routine.  
Scoring  
The question is rated on a 5 -point scale with responses ranging from “very unlikely” to “very 
likely.”  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
69 8.1.2.5.  EQ-5D-5L 
Description of EQ -5D-5L 
The EQ -5D-5L (EuroQol Research Foundation 2019) is a standardized, 5 -item, self -administered 
instrument for use as a measure of health outcome. It provides a simple descriptive health profile 
and a single health state index value that can be used in the clinical and economic evaluation of 
health care as we ll as population health surveys.  
The EQ -5D-5L asses ses 5 dimensions  of health  
 mobility  
 self-care 
 usual activities  
 pain or discomfort, and  
 anxiety  or depression.  
The 5L version scores each dimension at 5 levels  
 no problems  
 slight problems  
 moderate problems  
 severe problems, and  
 unable to perform  or extreme problems.  
A total of 3125 health states are possible.  
Scoring  
The scores on the 5 dimensions can be presented as a health profile or converted to a single 
health state index value.  
The single health state index value can be derived based on a formula that attaches weights to 
each of the levels in each dimension. This index value ranges between less than 0 to 1, where 
negative values are valued as worse than dead , 0 is a health state equ ivalent to death , and 1 
represents perfect health.  
EQ Visual Analog Scale  
The EQ Visual Analog Scale records the respondent’s self -rated health status on a vertical 
graduated visual analog scale  from 0 to 100, where 0 represe nts the worst imaginable health  and 
100 represents the best imaginable health . 
In conjunction with the health state data, this provides a composite picture of the respondent’s 
health status.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
70 8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations  
Physical examination at screening  
The complete physical examination will include , at a minimum,  assessments of these systems  
 cardiovascular  
 respiratory  
 gastrointestinal, and  
 neurologic . 
Height and weight will be measured and recorded.  
Additional assessments include clinical signs and symptoms  related to T2D , T2D-related 
illnesses , and injection site reac tions . 
8.2.2.  Vital Signs  
Blood pressure and pulse rate will be measured when specified in the SoA and as clinically 
indicated. Additional vital signs may be measured during study visits if warranted, as determined 
by the investigator.  
8.2.3.  Electrocardiograms  
Local and s ingle  12-lead ECG will be obtained as outlined in the SoA.  
Electrocardiograms will initially be interpreted by the investigator o r qualified designee at the 
site as soon after the time of ECG collection as possible, and ideally while the participant is still 
present, to determine whether the participant meets entry criteria and for immediate participant 
management, should any clinic ally relevant findings be identified.  
The investigator or qualified designee is responsible for determining if any change in participant 
management is needed and must document their review of the ECG printed at the time of 
evaluation.  
8.2.4.  Clinical Safety Labor atory Tests  
See Section 10.2 for the list of clinical laboratory tests to be performed and the So A for the 
timing and frequency.  
The investigator mus t review the laboratory results, document this review, and report any 
clinically relevant changes occurring during the study as an AE.  
The laboratory results must be retained with source documents unless a Source Document 
Agreement or comparable document cites an electronic location that accommodates the expected 
retention duration.  
Clinically significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by the investigator to be more severe than exp ected for the 
participant ’s condition.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
71 All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within 5 weeks after the last dose of intervention should be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by the 
investigator or medical monitor.  
If such values do not return to normal  or baseline within a period of time judged reasonable by 
the investigator, the etiology should be identifie d and the sponsor notified.  
All protocol -required laboratory assessments, as defined in Section 10.2, must be conducted in 
accordance with the SoA, s tandard collection requirements , and laboratory manual . 
If laboratory values from non -protocol -specified laboratory assessments performed at an 
investigator -designated local laboratory require a change in participant management or are 
considered clinically  significant by the investigator , for example, SAE or AE or dose 
modification, then report the information as an AE.  
8.2.5.  Hepatic Monitoring  
Close hepatic monitoring  
Initiating laboratory and clinical monitoring for abnormal liver laboratory test results  
Labora tory tests, including ALT, AST, ALP, TBL, direct bilirubin, GGT, and creatine kinase , 
should be repeated within 48 to 72 hours to confirm the abnormality and to determine if it is 
increasing or decreasing, if 1 or more of these conditions occur. This table  shows when to repeat 
laboratory tests.  
If a participant with baseline results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participants with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for participants with Gilbert’s 
syndrome)  
What to do if the abnormal condition persists or worsens  
If the abnormal liver test  result persists or worsens, clinical and laboratory monitoring, and 
evaluation for possible causes of abnormal liver tests should be initiated by the investigator in 
consultation with the Lilly -designated medical monitor. At a minimum, this evaluation sho uld 
include physical examination and a thorough medical history, including  
 symptoms  
 recent illnesses, for example, heart failure, systemic infection, hypotension, or seizures  
 recent travel  
 history of concomitant medications, including over -the-counter, herbal and dietary 
supplements, and  
 history of alcohol drinking and other substance abuse.  
Frequency of monitoring  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
72 Initially, monitoring of symptoms and liver tests should be done 1 to 3 times weekly, based on 
the participant’s clinical condition and liver  test results.  
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and laboratory results stabilize.  
Monitoring of ALT, AST, ALP, and TBL should continue until levels normalize or ret urn to 
approximate baseline levels.  
Comprehensive hepatic evaluation  
When to perform a comprehensive evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of the conditions in this table occur.  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs  or symptomsa, or 
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participants  with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs  or symptomsa, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for participants with Gilbert’s syndrome)  
a Hepatic signs  or symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, 
rash, and/or eosinophilia >5%.  
What a comprehensive evaluation should include  
At a minimum, this evaluation should include  
 physical examination and a thorough medical history, as outlined above  
 tests for  
o PT-INR 
o viral hepatitis A, B, C, or E , and  
o autoimmune hepatitis, and  
 an abdominal imaging study, for example, ultrasound or computed tomography scan.  
Based on the patient ’s history and initial results,  further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for  
 hepatitis D virus  
 cytomegalovirus  
 Epstein -Barr virus  
 acetaminophen levels  
 acetaminophen protein adducts  
 urine toxicology screen  
 Wilson ’s disease  
 blood alcohol levels  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
73  urinary ethyl glucuronide, and  
 blood phosphatidylethanol.  
Based on the circumstances and the investigator ’s assessment of the participant ’s clinical 
condition, the investigator should consider referring the participant for a hepa tologist or 
gastroenterologist consultation, magnetic resonance cholangiopancreatography, endoscopic 
retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in study participan ts who have 
abnormal liver tests during the study  
Collect additional hepatic safety data collection in the hepatic safety CRFs i f a participant 
develops  
 a hepatic event considered to be an SAE , or 
 discontinues study intervention due to a hepatic event, or 
 has changes in laboratory results described in this table . 
If a participant with 
baseline results of...  develops the following elevations…  Then…  
Elevated serum ALT  
Collect additional hep atic safety data in 
the hepatic safety CRF.  ALT <1.5x ULN  ALT to ≥5x ULN on 2 or more 
consecutive blood tests  
ALT ≥1.5x ULN  ALT ≥3x baseline on 2 or more 
consecutive blood tests  
Elevated TBL  
TBL <1.5x ULN  TBL ≥2x ULN , except for participants 
with Gilbert’s syndrome  
TBL ≥1.5x ULN  TBL ≥2x baseline  
Elevated ALP  
ALP <1.5x ULN  ALP ≥2x ULN on 2 or more consecutive 
blood tests  
ALP ≥1.5x ULN  ALP to ≥2x baseline on 2 or more 
consecutive blood tests  
Note: The interval between the 2 consecutive blood tests should be at least 2 days.  
See Section 10.5 for hepatic laboratory tests.  
8.2.6.  Pregnancy Testing  
Pregnancy testing will occur as outlined in the SoA.  
Details of all pregnancies in female participants and, if indicated, female partners of mal e 
participants will be collected as outlined in Sections 8.3.1  and 8.3.2 . 
8.3. Adverse Events , Serious Adverse Events , and Product Complaints  
The definitions of the following events can be found in Appendix 3:  
 adverse events (AEs)  
 serious adverse events (SAEs) , and  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
74  product complaints (PCs) . 
These events will be reported by the participant or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative.  
The investigator and any qualified designees are responsible for detecting, docu menting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention  or study (see Section 7). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits  or contacts. All SAEs  will be followed until resolution, stabi lization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). 
For product complaints, the investigator is responsible for ensuring that follow -up includes any 
supplemental investigations as indicated to elucidate the nature and/or causality. Further 
information on follow -up procedures is provided in Section  10.3. 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
75 8.3.1.  Timing and Mechanism for Collecting Events  
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Adverse Event  (AE)  
AE Signing of 
the informed 
consent form 
(ICF)  The last 
safety follow -
up visit  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  (SAE)  
SAE and SAE 
updates  
prior to start of 
study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  Signing of 
the ICF  Start of 
intervention  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
SAE and SAE  
updates  
after start of 
study 
intervention  Start of 
intervention  The last 
safety follow -
up visit  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
SAEa  
after study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  90 days  after 
the last dose  Within 24 hours  
(see Section  8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
76 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Product Complaints  (PC)  
PC associated 
with an SAE or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  Product Complaint 
form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  Product Complaint 
form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed Product 
Complaint form 
with all changes 
signed and dated by 
the investigator  N/A 
PC (if 
investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  Product Complaint 
form   
a Serious adverse events should not be reported unless the investigator deems them to be possibly 
related to study treatment  or study participation . 
8.3.2.  Pregnancy  
Collection of pregnancy information  
Male participants with partners who become pregnant  
The investigator will attempt to collect pregnancy information on any male participant’s female 
partner who becomes pregnant while the male participant is in this study. This applies only to 
male participants who receive LY3209590  or insulin degludec . 
After learning of a pregnancy in the female partner of a study participant, the investigator will  
obtain a consent  to release information  from the pregnant female partner directly, and within 24 
hours after obtaining this consent will record pregnancy information on the appropriate form and 
submit it to the sponsor.  
The female partner will also be followed to determine the outcome of the pregnancy. Information 
on the status of the mother and child will be forwarded to the sponsor. Gene rally, the follow -up 
will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the 
pregnancy will be reported regardless of gestational age,  fetal status (presence or absence of 
anomalies) , or indication for the procedur e. 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
77 Female participants who become pregnant  
The investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. The initial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning of a participant's 
pregnancy.  
The participant will be followed to determine the outcome of the pregnancy. The investigator 
will collect follow -up information on the participant and the neonate and the information will be 
forwarded to the sponsor. Generally, follow -up will not be required for longer than 6 to 8 weeks 
beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of 
gestational age,  fetal status (presence or absence of anomalies) , or indication for the procedure.  
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
A spontaneous abortion (occurr ing at <20 weeks ’ gestational age) or still birth (occurring at ≥20 
weeks ’ gestational age) is always considered to be an SAE and will be reported as such.  
Any post study  pregnancy -related SAE considered reasonably related to the study intervention by 
the investigator will be reported to the sponsor as described in protocol Section  8.3.1 . While the 
investigator is not obligated to actively seek this information in former study participants, they 
may learn of an SAE through spontaneous reporting.  
Any female participant who becomes pregnant while participating in the study will discontinue 
study intervention . If the participant is discontinued from the study, follow the standard 
discontinuation process and continue directly to the follow -up phase. T he follow -up on the 
pregnancy outcome should continue independent of intervention or study discontinuation.  
8.3.3.  Cardiovascular Events  
A blinded external Clinical Event Committee will adjudicate potential cerebrocardiovascular 
events in a consistent and unbiase d manner.  
Events include  
 death  
 myocardial infarction  
 coronary revascularization procedure  
 hospitalization for unstable angina  
 hospitalization for heart failure, and  
 stroke or Transient Ischemic Attack . 
8.3.4.  Systemic Hypersensitivity Reactions  
Many drugs, includ ing biologic agents, carry the risk of systemic hypersensitivity reactions. If 
such a reaction occurs, additional data should be provided to the sponsor in the designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical e quipment 
available when study participants are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
78 In the case of a suspected systemic h ypersensitivity event, additional blood samples should be 
collected as described in Section 10.2.1 . Laboratory results are provided to the sponsor via the 
central laboratory.   
8.3.5.  Injection Site Reactions  
Symptoms and signs of a local injection site reaction may include erythema, induration, pain, 
pruritus, lipodystrophy , and edema.  
If an injection site rea ction  is reported by a participant or s tudy personnel , additional information 
about this reaction will be collected in the CRF . 
8.3.6.  Hypoglycemia  
Participants will be trained by authorized study personnel about signs and symptoms of 
hypoglycemia and how to trea t hypoglycemia. Hypoglycemia events entered into the participant e -
diary will be available for review through a web -based portal that can be accessed by designated 
investigative site personnel at any time.  
Hypoglycemia classification and definitions  
Level 1 
Glucose <70  mg/dL (3.9  mmol/L) and ≥ 54  mg/dL (3.0  mmol/L)  
Level 1 hypoglycemia can alert a person to take action such as treatment with fast -acting 
carbohydrates. Providers should continue to counsel participants to treat hypoglycemia at this 
glucose al ert value.  
Level 2  
Glucose <54  mg/dL (3.0  mmol/L)  
Level 2 hypoglycemia is also referred to as documented or blood glucose -confirmed 
hypoglycemia. The glucose threshold is clinically  relevant regardless of the presence or absence 
of symptoms of hypoglycemia . 
Level 3 Severe  
A severe hypoglycemic event is characterized by altered mental or physical status requiring 
assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative  
actions  for the treatment of hypoglycemia.  
The determination of an episode of severe hypoglycemia is made by the investigator based on 
the medical need of the participant to have required assistance and is not predicated on the report 
of a participant simply having received assistance.  
Examples of seve re hypoglycemia in adults are  
 altered  mental  status  and the inability to assist in their own care  
 semiconscious or unconscious, or  
 coma  with or without  seizures . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
79 Glucose  measurements  may not be available during  such an event, but neurological recovery  
attributable to the restoration of  glucose concentration  to normal  is considered  sufficient  
evidence that the event was induced by  a low glucose concentration.  
Nocturnal hypoglycemia  
Nocturnal hypoglycemia is a hypoglycemia event, including severe hypoglycemia, that occurs at 
night  and presumably during sleep between midnight and 0600 (6:00 am).  
Reporting of severe hypoglycemic events  
If a hypoglycemic event meets the criteria of severe, the investigator must rec ord the event as 
serious on the AE CRF and report it to Lilly as an SAE.  
The investigator should also determine if repeated or prolonged episodes of hypoglycemia 
occurred prior to the severe event.  
8.4. Pharmacokinetics  
At the visits and times specified in the SoA, blood samples will be collected for all participants . 
Only samples from participants assigned to treatment with LY3209590  will be analyzed for drug 
concentration.  
Instructions for the collection and handling of blood samples will be provided by the sp onsor . 
The actual date and time (24 -hour clock time) of each sampling will be recorded.  
Bioanalytical  
Samples will be analyzed at a laboratory designated by the sponsor and stored at a facility 
designated by the sponsor. Concentrations of LY3209590 will be  assayed using a validated 
bioanalytical method.  
Sample retention is described in Section  10.1.12 .  
8.5. Pharmacodynamics  
Pharmacodynamic parameters a re described in Section 8.1. 
8.6. Genetics  
Genetics are not evaluated in this study.  
8.7. Biomarkers  
Serum and plasma samples will be used for exploratory biomarker research, where local 
regulations allow. See Clinical Laboratory Tests  in Section 10.2, and the SoA for sample 
collection information.  
Samples will be used for research on the drug target, disease process, variable response to 
LY3209590  pathways associated with T2D, mechanisms of action o f LY3209590  or research 
methods, or in validating diagnostic tools or assay(s) related to T2D.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
80 Samples may be used for research to develop methods, assays, prognostics , and/or companion 
diagnostics related to the intervention target, disease state, pathway s associated with disease, 
and/or the mechanism of action of the study intervention . 
Sample retention is described in  Section 10.1.12 .  
8.8. Immunogenicity Assessments  
At the visits and times specified in the SoA, venous blood samples from all study participants 
will be collected to determine antibody production against LY 3209590 . Antibodies may be 
further characterized for cross -reactive binding to endogenous insulin.  
To interpret the results of immunogenicity, a corresponding venous blood sample will be 
collected at the same visits to determine the concentrations of LY3209590  (PK sample) . At 
Visit  3, the sample for immunogenicity should be taken before dosing and  the PK sample for 
LY3209590 after dosing . 
Instructions for the collection and handling of blood samples will be provided by the sponsor.  
Treatment -emergent ADA s are defined in Section 9.3.6.2 . 
Immunogenicity will be  assessed by a validated assay designed  to detect and characterize ADA in the 
presence of LY3209590 at a laboratory approved by the sponsor.  
Sample retention is described in  Section 10.1.12 . 
8.9. Health Economic s 
Health economics parameters are not evaluated in this study . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
81 9. Statistical Considerations  
The first version of the SAP will be finalized prior to the first participant visit , and it will include 
a more technical and detailed description of the statistical analyses described in this section. This 
section is a summary of the planned statistical analyses of the most important endpoints, 
including primary and key secondary endpoin ts. 
9.1. Statistical Hypotheses  
Primary Hypothesis  
The primary objective of this study is to test the hypothesis that LY3209590 is no t inferior to 
insulin degludec on glycemic control as measured by change in HbA1c from baseline to Week 
52 (Visit 31) in partici pants with T2D  who are starting basal insulin for the first time.  
The null hypothesis ( H0) is the diff erence between LY 3209590 versus insulin degludec in the 
change from baseline to Week 52  (Visit 3 1) in HbA1c is greater than the NIM . 
The NIMs of 0.4% and 0.3% will both be tested to meet regulatory requirements. The 2 -sided 
95% CI will be used for testing the noninferiority.  
Secondary Hypotheses  
The key secondary objectives (multiplicity adjusted) are to test the hypotheses that LY3209590 
is 
 not inferior  to insulin degludec for change in HbA1c from baseline to Week 52  (Visit 3 1) 
for the subpopulation of participants using GLP -1 receptor  agonists  
H0: the difference (LY3209590 -insulin degludec)  >0.4%  
 not inferior to insulin degludec for change in HbA1c from baseline to Week 52  (Visit 3 1) 
for the subpopulation of participants not using  GLP -1 receptor agonists  
H0: the difference (LY3209590 -insulin degludec)  >0.4%  
 superior to insulin degludec for change in HbA1c from baseline to Week 52 (Visit 31)  
H0: the difference (LY3209590 -insulin degludec)  ≥0.0, and  
 superior to insulin degludec with respect to time in glucose range between 70 and 
180 mg/dL  (3.9 and 10.0 mmol/L)  inclusive , collected during the CGM collected session 
prior to Week 52  (Visit 31)  
H0: the difference (LY3209590 -insulin degludec)  ≤0.0. 
These hypotheses and the primary hypothesis will be tested using a strategy to control the overall 
Type 1 error  (see Section 9.1.1 ). 
9.1.1.  Multiplicity Adjustment  
A graphical approach (Bretz et al. 2009 , 2011) for multiple comparisons will be used to ensure 
the strong control of o verall type I error rate for testing the primary and key secondary 
(multiplicity adjusted) objectives.  
The overall significance level (α) will be set to 0.05. The total α will be used for the primary 
objective first, then the α will be allocated and transitioned to  other key secondary objectives 
once the primary objective is met. The testing procedure and α allocation will be established 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
82 according to the clinical importance and statistical power of the endpoints in this study 
population.  
The details o f graphical testing scheme will be described in the SAP.  
9.2. Analyses  Sets 
This table defines the populations for the purpose of analysis . 
Analysis Populations  or Data sets Description  
Entered Population  All participants who sign the  ICF. 
Randomized  Population  All randomized participants . Participants will be analyzed according  to 
the treatment they were assigned . 
 Modified Intent -to-Treat (mITT) 
Population  All randomized  participants who took at least 1 dose of study treatment.  
Participants will be  analyzed according to the treatment they were 
assigned.  
Efficacy Analysis Set 1 (EAS1) for 
treatment regimen estimand  The data will include   
 mITT Population excluding participants  discontinu ing the 
study treatment due to i nadver tent enrollment  
 all measurement  regardless of the use of study treatment or 
rescue medications  
Efficacy Analysis Set 2 (EAS2) for 
efficacy estimand  The data will include  
 mITT Population excluding participants discontinuing the 
study treatment due to inadvertent enrollment  
 measurement up to the discontinuation of study treatment or 
the initiation of rescue medication . 
Safety Analysis Set (SS)  The data will include  
 mITT Population  
 all measurement regardless of the use of study treatment or 
rescue medications  
9.3. Statistical Analyses  
9.3.1.  General Considerations  
Statistical analysis of this study will be the responsibility of Lilly or its designees. Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of t he protocol. Any other changes to the data analysis methods 
described in the protocol, and the justification for making the change, will be described in the 
SAP or the clinical study report. Additional exploratory analyses of data will be conducted as 
deem ed appropriate.  
Unless otherwise stated, the efficacy analyses will be conducted on either EAS1 or EAS2 , and 
the safety analyses will be conducted on the SS. All tests of treatment effects will be conducted 
at a 2 -sided alpha level of 0.05 and 2 -sided 95% confidence intervals will be calculated . 
Unless otherwise stated , the other secondary and tertiary efficacy measures will be analyzed 
using the data up to the discontinuation of study treatment  (EAS2) , defined by the date of last 
study dose +10 days or the  initiation of rescue medication , whichever is earlier . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
83 Handling of missing, unused, and spurious data are addressed prospectively in the overall 
statistical methods described in the protocol and in the SAP, where appropriate. Adjustments to 
the planned an alyses are described in the final CSR.  
9.3.2.  Primary Endpoint  or Estimand  Analysis  
The primary objective is to compare the HbA1c change from baseline to Week 52 between 
LY3209590 and insulin degludec and will be based on either of the se 2 estimands  
treatment regimen estimand for registration in the U nited States and 
efficacy estimand for registration in other countries.  
The 2 -sided 95% CI of the LS mean for individual treatment groups, treatment LS mean 
difference (LY3209590 – insulin degludec) in th e HbA1c change from baseline to Week 52  
(Visit 31 ) will be estimated.  
For both estimands, LY3209590 will be declared noninferior to insulin degludec if the upper 
limit of the 2 -side 95% CI for the LS mean difference in the HbA1c change from baseline is 
below NIM (+0.4% or +0.3% for different regulatory requirements).  
The HbA1c is reported in unit of % and will be converted to the unit of mmol/mol using the 
following formula:  
HbA1c in mmol/mol = 10.93 * HbA1c in % - 23.5 (http://www.ngsp.org/ifccngsp.asp).  
Treatment regimen estimand  
The treatment regimen estimand will be based on  the HbA1c data at baseline and Week 52  (Visit 
31) from the EAS1, regardless of the use of study intervention or rescue medications.  
Missing measures  
Missing measures at the primary endpoint will be imputed using multiple imputation by the 
retrieve d dropout approach. The retrieved dropout participants are those who discontinue study 
intervention prior to Week 52 (Visit 31 ) but have non -missing measures at Week 52 (Visit 31 ). 
If there are only a limited number of retrieved participants that leads to a failure in performing 
the multiple imputation analysis, such as the model cannot converge, or the number of retrieved 
dropout participants is small, the missing HbA1c at Week 52  (Visit 31) will be imputed by 
return -to-baseline multiple imputations.  
Analysis model  
After the imputation, the observed and imputed data will be analyzed by the ANCOVA.  
The model will include treatment , strata (country, GLP -1 RA treatment at randomization , and SU 
use at randomization ), and baseline value of the dependent variable. The statistical inference will 
be based on the multiple imputation framework by Rubin (1987).  
Efficacy estimand  
The efficacy estimand is the treatment difference in the change of HbA1c from baseline to Week 
52 (Visit 3 1) if all participants adhere to the treatment without intercurrent events.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
84 The HbA1c collected at all planned postbaseline visits  from the EAS2 will be used in the 
analysis . 
Missing measures  
There may be missing values due to the early discontinuation of study treatment or use of rescue 
medication.  
Analysis model  
The MMRM model will be used, and the missing values will be handled  implicitly in the 
MMRM analysis under the assumption of missing at random. The MMRM m odel will include 
treatment, strata (country , GLP -1 RA treatment  at randomization and SU use  at randomization), 
visit and treatment -by-visit interaction as fixed effects, and baseline of the dependent variable as 
a covariate. The Kenward -Roger approximatio n will be used to estimate denominator degrees of 
freedom for the MMRM models.  
An unstructured covariance structure will be used to model the within -participant errors. If this 
structure fails to converge, the following covariance structures will be used i n order until one 
converges : 
1. Toeplitz with heterogeneity  
2. autoregressive with heterogeneity  
3. compound symmetry with heterogeneous variances  
4. Toeplitz  
5. Autoregressive  
6. compound symmetry without heterogeneous variances.  
9.3.3.  Secondary Endpoint s Analysis  
9.3.3.1.  Multiplicity -Adjusted Endpoints  
A graphical approach will be used to control the overall type I error for the primary objective and 
testing of key s econdary objectives as described  in Section 9.1. 
Noninferiority test  
The noninferiority test in change from baseline to Week 52  (Visit 3 1) in HbA1c for the 
subpopulations will be based on the  ANCOVA model for treatment regimen  estimand  (using data 
from the EAS1) and an MMRM model for efficacy estimand  (using data from the EAS2)   
In the ANCOVA model, treatment, strata (country  and SU use at randomization ), and baseline of 
the dependent variable will be used as covariates.  
The MMRM model w ill include treatment, strata (country  and SU use at randomization ), visit 
and treatment -by-visit interaction as fixed effects, and baseline of the dependent variable as a 
covariate.  
For the treatment regimen estimand, the missing data will be imputed by multiple imputation 
with the approach similar to the imputation used for the primary endpoint.   
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
85 Superior ity test 
The superiority test in change from baseline to Week 52  (Visit 31) in HbA1c wi ll be based on the 
same primary endpoint analysis described above.  
The time in glucose range between 70 and 180  mg/dL (3.9 and 10.0 mmol/L)  inclusive , 
measured by CGM , will be analyzed using an ANCOVA model  for treatment regimen estimand 
and a n MMRM model for efficacy estimand . In the  ANCOVA  model, treatment, strata (country, 
baseline  HbA1c stratum [<8.0%, ≥8.0%], GLP -1 RA treatment at randomization , and SU use  at 
randomization ), and baseline of the dependent variable will be used  as covariates . The MMRM 
model will include treatment, strata (country, baseline HbA1c stratum [<8.0%, ≥8.0%], GLP -1 
RA treatment at randomization , and SU use at randomization ), visit and treatment -by-visit 
interaction as fixed effects, and baseline of the dependent variable as a covariate.  For treatment 
regimen estimand, the missing data  will be imputed by multiple imputation with the approach 
similar to the imputation  used for the primary endpoint.  
9.3.3.2.  Other Secondary Endpoints  
Other secondary endpoints include various measures for efficacy, safety , and patient -reported 
outcome questionnaires.  
Efficacy measures and patient -reported questionnaires will be analyzed using the EAS2 unless 
otherwise noted . 
Safety measures will be analyzed using the SS regardless of treatment discontinuation and use of 
rescue medications.  
Analysis details will be provided in the SAP.  
9.3.4.  Tertiary  Endpoint (s) Analysis  
Refer to the SAP for analyses related to tertiary endpoints.  
9.3.5.  Safety Analyse s 
Safety Measures Include  
 treatment exposure  
 AE 
 vital signs  
 weight  
 hypoglycemia  
 laboratory measures and  
 immunogenicity.  
All safety analyses will be based on the SS. 
Events that are newly reported after the first dose of LY3209590 or insulin degludec , or reported 
to worsen in severity from baseline , will be co nsidered TEAEs. The Medical Dictionary for 
Regulatory Activities (MedDRA) lowest level term will be used in the treatment -emergent 
assessment. The maximum severity for each lowest level term  during the baseline period will be 
used as baseline severity.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
86 Summary statistics will be provided for incidence of  
 TEAEs  
 SAEs  
 study discontinuation due to AEs  
 intervention discontinuation due to AEs, and  
 deaths . 
Hypoglycemia analysis  
The participant -reported hypoglycemia  will be analyzed using data from the e-diary  by 
 Level 1 (defined by glucose value ≥54 to <70  mg/dL [≥3.0 to <3.9mmol/L] ) 
 Level 2 (defined by glucose <54  mg/dL  [<3.0 mmol/L] ) 
 Level 3 (severe hypoglycemia) , and 
 the composite of Level s 2 and 3.  
The analysis periods of 0 -6, 0-12, 0 -26, 0 -52, 12 -26, and 26-52 weeks of treatment will be 
considered. Documented h ypoglycemia will be defined as  
 All documented hypoglycemia - episodes for the 24 -hour period  
 Non-nocturnal hypoglycemia  - episodes during  6 AM to midnight, and  
 Nocturnal hypoglycemia  - episodes during  midnight to 6 AM.  
The incidence and rate of hypoglycemia will be summarized by treatment and analysis period for 
different types of hypoglycemia.  
For continuous safety variables (for example, laboratory measures, vital signs and weight), 
MMRM or ANCOVA m odels will be used. For categorical safety variables (for example, AEs, 
incidence of hypoglycemia, and treatment -emergent abnormal laboratory measurements), either 
Fisher’s exact test or logistic regression will be used for treatment comparison.  
Further de tails for assessing all safety measures will be described in the SAP.  
9.3.6.  Other Analysis  
9.3.6.1.  Pharmacokinetic and Pharmacodynamic Analyses  
LY3209590 concentration data will be analyzed using a population PK approach via nonlinear 
mixed -effects modeling with the NON MEM software.  
The relationships between LY3209590 dose and/or concentration and efficacy, and safety as well 
as biomarker endpoints may be characterized. In addition, if population PK and PK/PD models 
can be established, the impact of additional participan t factors, such as age, weight, sex, and 
renal function on PK and/or PD parameters, may be examined. Should anti -drug antibody be 
detected from immunogenicity testing, its impact on LY3209590 PK or any relevant PD 
parameters will also be examined.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
87 9.3.6.2.  Evaluati on of Immunogenicity  
The baseline anti -LY3209590 -antibody ( ADA ) status (detected or not detected) will be 
summarized by treatment for the participants evaluable for TEADA defined as participants with 
non-missing baseline and at least 1 non-missing postbaseline measurement.  
The number and percentage of  participants who are treatment -emergent ADA -positive 
(TEADA+) will be summarized by treatment group.  
The frequency of cross -reactive binding to endogenous insulin s may also be summarized f or the 
participants with TEADA+.  
The relationship between the presence of TEADA and the safety and efficacy measures may be 
assessed.  
Definition of TEADA+  
A participant is considered TEADA+ if either treatment -induced ADA or treatment -boosted 
ADA occur s. 
Treatment -induced ADA  is defined as the participant ha ving a  baseline status of ADA Not 
Present and at least 1 postbaseline status of ADA Present with titer ≥ 2 -fold (1 dilution) of the 
minimum required dilution (1:20)  
Treatment -boosted ADA  is defined as  the participant ha ving a  baseline status of ADA Present 
and at least 1 postbaseline status of ADA Present with the titer being ≥2 dilutions (4 -fold) of the 
baseline titer.  
9.3.7.  Subgroup Analyses  
The following outcomes will be analyzed by the s ubgroup s of GLP -1 RA use at randomization : 
 rate of Level 1 hypoglycemia events during Weeks 0 to 26, Weeks 26 to 52, and Weeks 0 to 
52 
 rate of composite of Level 2 and 3  hypoglycemia events during Weeks 0 to 26, Weeks 26 to 
52, and Weeks 0 to 52  
 change from baseline to Week 26 and Week 52 in body weight  
 insulin dose at Week 26 and Week 52  
 measurements collected during CGM sessions collected  prior to Weeks 12, 26 , and 52 of  
o time in hypoglycemia with glucose <70  mg/dL  (3.9 mmol/L )  
o time in hypoglycemia with glucose <54  mg/dL  (3.0 mmol/L ) 
o time in hyperglycemia defined as glucose >180  mg/dL  (10.0 mmol/L ), and  
o time in glucose range between 70 and 180  mg/dL  (3.9 and 10.0 mmol/L , 
respectively ), inclusive.  
The analyses will evaluate whether the treatment impact  is different by  the subgroups . The 
models used for these analyses will vary depending on the outcome. Other subgroup analyses 
may be performed as deemed appropriate.  
Details of the modeling will be provided in the SAP.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
88 9.4. Interim Analysis  
A program level -safety review using  selected efficacy and safety data will be conducted on a 
periodic basis across all ongoing Phase 3 clinical trials evaluating LY3209590. The analysis will 
be performed using the unblinded data and be reviewed by the DMC consisting of experienced 
members e xternal to Lilly  (Section 10.1.5 ). 
Study team personnel will remain blinded. Detailed information for the data review and the 
unblinding are specifie d in the DMC charter or a separate unblinding plan document.  
9.5. Sample Size Determination  
Approximately 888 participants will be randomly assigned to LY3209590 and insulin degludec 
in a 1:1 ratio. With the assumption of 15% dropout at Week 52, approximately 377 and 377 
participants will complete 52 weeks of treatment on LY3209590 and insulin degludec, 
respectively.  
The primary objective of this study is to test the hypothesis that LY3209590 is noninferior to 
insulin degludec on glycemic control as measured by  change from baseline to Visit 31 (Week 
52) in HbA1c in participants with T2D who are starting basal insulin for the first time.  754 
completers (377 on LY3209590 and 377 on insulin degludec) will provide an at least 9 9% 
statistical power to show noninferio rity between LY3209590 and insulin degludec using the 
upper limit of a 2 -sided 95% confidence interval (LY3209590 – insulin degludec) and these 
assumptions  
 NIM of 0.4 % 
 no true difference between treatment groups, and  
 an SD of 1.1% . 
This sample size also ha s at least 95% statistical power to show noninferiority between 
LY3209590 and insulin degludec using a 0.3% NIM at Week 52.  
The number of participants in each subpopulation of background treatment will be approximately 
50% of the study population with bala nced treatment assignment to support the following 
secondary objectives , controlled for Type 1 error:  
To demonstrate noninferiority of LY3209590 to insulin degludec in HbA1c change from 
baseline to Week  52 for the subpopulation of participants using  GLP -1 RAs 
To demonstrate noninferiority  of LY3209590 to insulin degludec in HbA1c change from 
baseline to Week 52  for the subpopulation of participants not using  GLP -1 RAs. 
In each subpopulation, 188 completers  for each study intervention  will provide an approximately  
90% statistical power to show noninferiority between LY3209590 and insulin degludec using the 
upper limit of a 2 -sided 95% confidence interval (LY3209590 – insulin degludec)  and these 
assumptions  
 a NIM of 0.4 % 
 no true difference between treat ment groups, and  
 an SD of 1.1% . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
89 The 754 completers will provide 95% statistical power to demonstrate the superiority of 
LY3209590 versus insulin degludec, of change in HbA1c from baseline to 52 weeks, assuming 
an SD of 1.1% and true mean difference is -0.3%, using the alpha of 0.05.  
The 7 54 completers will provide at least 95% statistical power to show the superiority of the 
percentage of time in glucose range between 70 and 180  mg/dL (3.9 and 10.0 mmol/L)  inclusi ve 
during the CGM session prior to Week 52 between LY3209590 and insulin degludec , assuming 
an SD of 18% and true mean difference is 5% , using the  alpha of 0.05.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
90 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and S tudy Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsink i and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines  
o Applicable ICH GCP Guidelines  
o International Organization for Standardization (ISO) 14155 , and   
o Applicable laws and regulations . 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents , 
for example , advertisements , must be submitted to an IRB/IEC by the investigator and reviewed 
and approved by the IRB/IEC  before the study is initiated.  
Any amendments to the pr otocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require healt h authority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study 
participants . 
The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
○ Notifying the IRB/IEC of SAEs  or other significant safety findings as required by 
IRB/IEC procedures  
○ Providing oversight of study condu ct for participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations (C FR), ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies , if 
applicable, and all other applicable local regulations , and 
o Reporting significant issues related to participant safety, participant rights, or data 
integrity . 
Investigator sites are compensated for participation in the study  as detailed in the Clinical Trial 
Agreement . 
10.1.2.  Financial Disclosure  
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
91 certification or disclosure statements to the appropriate regulatory authorities. Investi gators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process  
The investigator or the investigator’s  representative will explain the nature of t he study , 
including the risks and benefits,  to the participant and answer all  questions regarding the study.  
Participants must be informed that their participation is voluntary. Participants will be required to 
sign a statement of informed consent that mee ts the requirements of 21 Code of Federal 
Regulations 50, local regulations, ICH guidelines, privacy and data protection requirements, 
where applicable, and the I RB/IEC or study center.  
The medical record must include a statement that written informed cons ent was obtained before 
the participant was enter ed in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants must be reconsented to the most current version of the  ICF(s) during th eir 
participation in the study.  
A copy of the ICF(s) must be provided to the participant and is kept on file . 
10.1.4.  Data Protection  
Participants will be assigned a unique identifier by the sponsor. Any participant records , datasets , 
or tissue sa mples  that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identi fiable will not be transferred.  
The participant must be informed that the participant’s  personal study -related data will be used 
by the sponsor in accordance with local data protection law. The level of disclosure must also b e 
explained to the participant  who will be required to give consent for their data to be used as 
described in the informed consent . 
The participant must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
The sponsor has processes in place to ensure data protection, information security , and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data security breach.  
10.1.5.  Committees Structure  
10.1.5.1.  Inter nal Safety Review Team  
Participant  safety will be continuously monitored by the sponsor’s internal safety review team, 
which includes safety signal detection at any time during the study.  
All safety data collected will be summarized and reviewed by the spo nsor’s internal safety 
review team  for agreement of next steps . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
92 10.1.5.2.  Clinical Event  Committee  for Adjudication of Events  
A blinded Clinical Event Committee, external to Lilly, will adjudicate  all deaths and 
cerebrocardiovascular events.  The committee will include physicians external to Lilly with 
cardiology expertise.  
10.1.5.3.  Data Monitoring Committee  
An independent, external DMC will be responsible for reviewing unblinded data during  the 
study.  
The committee will include, at a minimum, a medical physician  with app ropriate expertise and a 
statistician.  
Access to the unblinded data will be limited to the DMC and the external Statistical Analysis 
Center statisticians who are providing the analysis of the data. These statisticians will be 
independent from the study tea m. The study team will not have access to the unblinded data. 
Only the DMC is authorized to evaluate unblinded interim analyses.  
Details about the membership, purpose, responsibilities , and operation will be included in the 
DMC charter.  
10.1.6.  Dissemination of Cl inical Study Data  
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by local law or regulation.  
The summary of results will be posted within the time frame specified by local law or regulation. 
If the study remains ongoing in some countries and a statistical analysis of an incomplete data set 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overal l analyses (for example, trial not yet unblinded), the summary of results 
will be submitted within 1 year after the end of the study globally or as soon as available, 
whichever is earlier.  
Data  
The sponsor provides access to all individual participant data  collected during the trial, after 
anonymization, with the exception of pharmacokinetic or genetic data.  
Data are available to request 6 months after the indication studied has been approved in the US 
and EU and after primary publication acceptance, whiche ver is later. No expiration date of data 
requests is currently set once data are made available.  
Access is provided after a proposal has been approved by an independent review committee 
identified for this purpose and after receipt of a signed data sharing  agreement.  
Data and documents, including the study protocol, SAP, clinical study report, and blank or 
annotated case report forms, will be provided in a secure data -sharing environment for up to 2 
years per proposal.  
For details on submitting a request, s ee the instructions provided at www.vivli.org.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
93 10.1.7.  Data Quality Assurance  
Investigator responsibilities  
All participant data relating to the study will be recorded on printed or electronic CRF s unless 
transmitted to the sponsor or designee electronically , for example , laboratory data.  
The investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.  
The investigator must maintain accurate documentation (source data) that supports the 
inform ation entered in  the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct a ccess to source data documents.  
Data monitoring and management  
Quality tolerance limits will be pre -defined to identify systematic issues that can impact 
participant safety and/or reliability of study results. These pre -defined parameters will be 
monitored during the study and important excursions  from the quality tol erance limits  and 
remedial actions taken will be summarized in the clinical study report . 
Monitoring details describing strategy ( for example , risk -based initiatives in operations and 
quality such as risk management and mitigation strategies and analytical  risk-based monitori ng), 
methods, responsibilities and requirements, including handling of noncompliance issues and 
monitoring techniques are provided in the Monitoring Plan.  
The sponsor or designee is responsible for the data management of this study , includin g quality 
checking of the data.  
The sponsor assumes accountability for actions delegated to other individuals , for example , 
contract research organizations . 
Study monitors will perform ongoing source data verification to confirm that data transcribed 
into the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol  and any other study 
agreements, ICH GCP, and all applicable regu latory requirements.  
Records retention and audits  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the investigator for the time perio d outlined in the Clinical Trial Agreement (CTA)  
unless local regulations or institutional policies require a longer retention period. No records may 
be destroyed during the retention period without the written approval of the sponsor. No records 
may be tr ansferred to another location or party without written notification to the sponsor . 
In addition, sponsor  or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study site. The study may be a udited by sponsor  or its 
representatives, and/or regulatory agencies at any time. Investigators will be given notice before 
an audit occurs.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
94 Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
Electronic data capture system  
An EDC system will be used in this study for the collection of CRF data. The investigator 
maintains a separate source for the data entered by the investigator or designee into t he 
sponsor -provided EDC system. The investigator is responsible for the identification of any data 
to be considered source and for the confirmation that data reported are accurate and complete by 
signing the CRF . 
Additionally, clinical outcome assessment ( COA) data , participant -focused outcome instrument , 
and other data will be collected by the participant , caregiver , or authorized study personnel , 
using  a paper source document and will be transcribed by the authorized study personnel  into the 
EDC system  via direct data captured in the EDC system and will serve as the source 
documentation . 
Additionally, electronic clinical outcome assessment  (eCOA) data ( participant -focused outcome 
instrument ) will be directly recorded by the participant  or study  personnel , into an instrument , for 
example, hand held smart phone or tablet . The eCOA data will serve as the source 
documentation , and the investigator does not maintain a separate written or electronic record of 
these data.  
Data storage and access  
Data collected via  the sponsor -provided data capture system s will be  stored at third parties . 
The investigator will have continuous access to the data during the study and until 
decommissioning of the data capture system s. Prior to decommissioning, the investigator will 
receive or access an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system , and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the sponsor  data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.8.  Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data reported  on or entered in the CRF and are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator 
may need to request previous medical records or transfer records, depending on the study.  Also, 
current medical records must be available.  
Definition of what constitutes source data can be found in 10.1.7 . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
95 10.1.9.  Study and Site Start and Closure  
First Act of Rec ruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
Study or Site Termination  
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the stud y 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has be en performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigat or may include but are 
not limited to  
 study termination  
o discontinuation of further study intervention development  
 site termination  
o failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the spo nsor’s procedures, or GCP guidelines  
o inadequate recruitment (evaluated after a reasonable amount of time) of 
participants by the investigator , or 
o total number of participants included earlier than expected . 
If the study is prematurely terminated or suspend ed, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by the applicable 
regulatory requireme nts. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
10.1.10.  Publication Policy  
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.11.  Investigator Information  
Researchers with appropriate education, training, and experience, as determined by the sponsor, 
will participate as investigators in this clin ical trial.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
96 10.1.12.  Sample Retention  
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development of 
LY3209590 or after LY3209590 become(s) commercially available.  
Sample Type  Custodian  Maximum Retention Period after Last Patient Visita 
Exploratory biomarkers   Sponsor or designee  15 years  
Pharmacokinetic  Sponsor or designee  1 year 
Immunogenicity   Sponsor or designee  15 years  
a Sample  retention period s may differ dependent upon  local regulations.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
97 10.2. Appendix 2: Clinical Laboratory Tests  
The tests detailed in the table below will be performed by the Lilly -designated laboratory or by 
the local laboratory as specified in the table below . 
Local laboratory results are only required in the event that the central laboratory results are not 
available in time for either study intervention administration and/or response evaluation. If a 
local sample is required, it is important that the sample fo r central analysis is obtained at the 
same time. Additionally, if the local laboratory results are used to make either a study 
intervention decision or response evaluation, the results must be recorded.  
In circumstances where the sponsor approves local lab oratory testing in lieu of central laboratory 
testing (in the table below), the local laboratory must be qualified in accordance with applicable 
local regulations.  
Protocol -specific requirements for inclusion or exclusion of participants are detailed in Se ction 5 
of the protocol.  
Additional tests may be performed at any time during the study as determined necessary by the 
investigator or required by local regulations.  
Investigators must document their  review of the laboratory safety results . 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
98 Clinical Laboratory Tests   Comments  
Hematology  Assayed by Lilly -designated laboratory  
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs - red blood cells)   
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Leukocytes (WBCs - white blood cells)    
Differential    
Percent and absolute count of:   
  Neutrophils, segmented    
  Lymphocytes    
  Monocytes    
  Eosinophils    
  Basophils    
Platelets    
Clinical Chemistry  Assayed by Lilly -designated laboratory  
Sodium    
Potassium    
Chloride    
Bicarbonate    
Total bilirubin    
Direct bilirubin    
Alkaline phosphatase (ALP)    
Alanine aminotransferase (ALT)    
Aspartate aminotransferase (AST)    
Gamma -glutamyl transferase (GGT)    
Blood urea nitrogen (BUN)    
Creatinine    
Uric acid    
Total protein    
Albumin    
Calcium    
Phosphorus    
Glucose  Fasting or random (Refer to S oA) 
Cholesterol    
Triglycerides    
Lipid Panel  Assayed by Lilly -designated laboratory  
High -density lipoprotein (HDL)    
Low-density lipoprotein (LDL -C) This value will be calculated. If triglycerides >400  mg/dL, 
the direct LDL will be assayed  
Very -low-density lipoprotein (VLDL -C)   
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
99 Urinalysis  Assayed by Lilly -designated laboratory  
Speci fic gravity    
pH   
Protein    
Glucose    
Ketones    
Bilirubin    
Urobilinogen    
Blood    
Nitrite    
Urine leukocyte esterase    
Microscopic examination of sediment    
Hormones (female)    
Serum pregnancy  Assayed by Lilly -designated laboratory  
Urine pregnancy  Evaluated locally  
Follicle -stimulating hormone (FSH)  Assayed by Lilly -designated laboratory. Performed as 
needed to confirm participant’s postmenopausal status  
Urine Chemistry  Assayed by Lilly -designated laboratory  
Albumin   
Creatinine   
Calculations  Generated by Lilly -designated laboratory  
eGFR (CKD -EPI)    
Urinary albumin/creatinine ratio (UACR)    
Pharmacokinetic Samples  
LY3209590 concentration  Assayed by Lilly -designated laboratory  
Results will not be provided to the investigative sites 
Additional Testing  Assayed by Lilly -designated laboratory  
C-Peptide    
HbA1c    
Glucose  Fasting per SoA  
Exploratory Biomarker Storage Samples  Assayed by Lilly -designated laboratory  
Results will not be provided to the investigative sites  
Serum    
Plasma (EDTA)    
Immunogenicity Samples  Assayed by Lilly -designated laboratory  
Results will not be provided to the investigative sites  
Anti-LY3209590 antibodies    
 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
100 10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic  Hypersensitivity 
Event  
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory test results from these samples to characterize 
hypersen sitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized.  
Obtain follow -up pre dose samples at the next regularly scheduled laboratory sample collection , 
ideally prior to the next dose after the event , to assess post -event return -to-baseline values.  
Timing  Sampl e Type  Laboratory Testa 
Collect from 30 min to 4 hr after 
the start of the event.  
Note: The optimal collection time 
is from 1 to 2 hr after the start of 
event.  Serum  Total tryptase  
Serum  Complements ( C3, C3a, and C5a)  
Serum  Cytokine panel ( IL-6, IL‐1β, IL‐10 , or any cytokine 
panel that includes these 3 cytokines)  
Collect samples on the same day as 
the event.  
If samples were already collected 
per the SoA on the same day as the 
event, then duplicate samples are 
not collected.  
Note: The optimal collection time 
is up to 12 hr after the start of the 
event.  Serum  LY3209590  ADA s 
Plasma  LY3209590  concentration  
Abbreviations: ADA = anti -drug antibodies; IL = interleukin.  
a All samples for hypersensitivity testing will be assayed by Lilly -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protoco l deviation.  
Information to record  
Record the date and time when the samples are collected.  
Allowed additional testing for participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant ma nagement.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
101 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting  
 The definitions and procedures detailed in this appendix are in accordance with 
International Organization for  Standardization 14155.  
 Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.1  for the list of 
sponsor medical devices.  
10.3.1.  Definition of AE  
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavo rable  and unintended sign 
(including an abnormal laboratory finding), symptom, or disease  (new or exacerbated)  
temporally associated with t he use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
 An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory finding) i n study participants, users, or 
other persons, whether or not related to the investigational medical device. This 
definition includes events related to the investigational medical device or comparator 
and events related to the procedures involved except fo r events in users or other 
persons, which only include events related to investigational devices.  
 
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( for ex ample , ECG, radiological scans, and vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator , that is , not related 
to progression of underlying diseas e. 
 Exacerbation of a chronic or intermittent pre existing  condition , including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been presen t before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of IMP, including signs, symptoms, or clinical 
sequelae. See definitions in Section 10.9. 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
102  Lack of efficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, sy mptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfil l the definition of an AE or SAE.  
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
 The disease  or disorder being studied or expected progression, signs or symptoms of 
the disease  or disorder being studied, unless more severe than expected for the 
participant’s condition.  
 Medical or surgical procedure ( for example , endoscopy and appendectomy): the 
condi tion that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day -to-day fluctuations of pre existing  disease(s) or condition(s) present or 
detec ted at the start of the study that do not worsen.  
10.3.2.  Definition of SAE  
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospitalizatio n or prolongation of existing hospitalization  
 In general, hospitalization signifies that the participant has been admitted to  hospital or 
emergency ward (usually involving at least an overnight stay) for observation and/or 
treatment that would not have bee n appropriate in the physician’s office or outpatient 
setting. Complications that occur during hospitalization are AEs. If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is serious. When 
in doubt as to whether hos pitalization occurred or was necessary, the AE should be 
considered serious.  
 Hospitalization for elective treatment of a pre existing  condition that did not worsen 
from baseline is not considered an AE.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
103 d. Results in persistent disability/incapacity  
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, i nfluenza, 
and accidental trauma ( for example , sprained ankle) , which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes , for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, and ectopic pregnancy , are considered SAEs.  
f. Other situations  
 Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations , such as important medical 
events that may not be immediately life -threatening or result in death or hospitalization 
but may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the other outcomes li sted in the above definition. These events should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias , or 
convulsions that do not result in hospitalization, or development of drug dependency or 
drug abuse.   
g. Result s in medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.   
 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
104 10.3.3.  Definition of Product Complaints  
Product Complaint  
 A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness , 
or performance of a study intervention . When the ability to use the study intervention 
safely is impacted, the following are also product complaints:  
o deficiencies in labeling information, and  
o use errors for device or drug-device combination products due t o ergonomic 
design elements of the product.  
 Product complaints related to study inte rventions used in clinical trials are collected in 
order to ensure the safety of participants, monitor quality, and to facilitate process and 
product improvements.  
 Investig ators will instruct participants to contact the site as soon as possible if they 
have  a product complaint or problem with the study inte rvention so that the situation 
can be assessed.  
 An event may meet the definition of both a product complaint and an AE/S AE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints  
AE, SAE , and Product Complaint  Recording  
 When an AE/SAE /product complaint  occurs, it is the responsibility of the investigator 
to review all documentation ( for example , hospital progress notes, laboratory reports, 
and diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /product complaint  information 
in the participant’s medical records, in accordance with the investigator’s normal 
clinical practice. AE/SAE information is reported on the appropriate CRF page and 
product complaint  information is reported on the Product Complaint Form . 
Note: An event may meet the definition of both a product complaint and an AE/SAE. 
In such cases, it should be reported as both a product complaint  and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to Sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the Product Complaint Form for product complaints . 
 There may be instances when copies of medical records for certain cases are requested 
by Sponsor or designee . In this cas e, all participant identifiers, with the exception of 
the participant number, will be redacted on the copies of the medical records before 
submission to Sponsor or designee . 
 The investigator will attempt to establish a diagnosis of the event based on signs , 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.   
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
105 Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:  
 Mild:  A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
 Moderate:  A type of adverse event that is usually alleviate d with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of adverse event that interru pts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention . 
An AE that is assessed as severe should not be confused with a n SAE. Severe is a 
category utilized for rating the intensity o f an event , and both AEs and SAEs can be 
assessed as severe.  
An event is defined as “serious ” when it meets at least one of the pre -defined  outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.   
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  The investigator will use clinical judgment to 
determine the relationship/  
 A “reasonable possibility ” of a relationship conveys that there a re facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of t he event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB for LY3209590 and the Product Information  
for degludec  in their assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that they have 
reviewed the AE/SAE and have  provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Sponsor or designee . However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to Sponsor or designee . 
 The investigator may change their opinion of causality in light of follow -up 
information and send a n SAE follow -up report with the updated causality assessment.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
106  The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -Up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor or 
designee  to elucidate the nature and/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period,  the inv estigator will provide Sponsor or designee  with a copy of any 
post-mortem findi ngs, including histopathology.  
10.3.5.  Reporting of SAEs  
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see 
next section) to report the event within 24 hours.  
 The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
 After t he study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a n SAE paper form (see next 
section) or to the sponsor  by telephone.  
 Contacts for SAE reporting can be found in site training documents .  
 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the sponsor . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in site training documents . 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
107 10.3.6.  Regulatory Reporting Requirements  
SAE Regulatory Reporting  
 Prompt notification by the investigator to the  sponsor of a n SAE is essential so that 
legal obligations and ethical responsibilities toward  the safety of participants and the 
safety of a study intervention under clinical investigation are met.  
● The sponsor has a legal responsibility to notify both th e local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority , 
IRB/IEC , and investigators.  
● An investigator who receives an investigator safety report describing a n SAE or 
other specific safety information , for example , summary or listing of SAEs , 
from the sponsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.   
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
108 10.4. Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions  
Women of childbearing potential  (WOCBP)  
Females are considered wom en of childbearing potential if  
 they have had at least  1 cycle of menses, or  
 they have Tanner 4 breast development.  
Any amount of spotting should be considered menarche.  
Women not of childbearing potential  
Females are considered women not of childbearing potential if  
 they have a congenital anomaly , such as Mu llerian agenesis,  
 they are infertile due to surgical sterilization, or  
 they are postmenopausal.  
Examples of surgical sterilization include hysterectomy, bilateral oophorectomy, and tubal 
ligation.  
Postmenopausal  
The postmenopausal state should be defined as 
 a woman at any age at least 6 weeks post -surgical bilateral oophorectomy with or without 
hysterectomy, confirmed by operative note  
OR 
 a woman at least 40 years of age and up to 55 years old with an intact uterus, not on 
hormone therapy⸸, who has had ces sation of menses for at least 12 consecutive months 
without an alternative medical cause, AND with a follicle -stimulating hormone  
>40 mIU/mL  
OR 
 a woman 55 years of age or older not on hormone therapy, who has had at least 12 
months of spontaneous amenorrhea  
OR 
 a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone 
replacement therapy.  
⸸ Women should not be taking m edications during amenorrhea , such as oral contraceptives, 
hormones, gonadotropin -releasing hormone, anti -estrogens, selective estrogen receptor  
modulator s, or chemotherapy that could induce transient amenorrhea.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
109 10.4.2.  Contraception Guidance  
Guidance for women  of childbearing potential  
This outlines the rules for WOCBP to ensure they do not become pregnant during the study.  
If, as part of their preferred and usual lifestyle, 
WOCBP…  Then…  
are in a same -sex relationship   they must stay in same -sex relationships without 
sexual relationships with males, and  
 take pregnancy tests.  
are completely abstinent   they must agree to remain completely abstinent  
are not completely abstinent   they must agree to  
o use 1 highly effective method (less than 
1% failure rate) of contra ception, or a 
combination of 2 effective methods of 
contraception.  
o take pregnancy tests.  
 these forms of contraception must be used for 
the duration of the study . 
Note on forms of contraception:  At least 1 form of contraception must be highly effective, m eaning that it has a 
less than 1% failure rate.  
 
Guidance for all men  
No male contraception is required except in compliance with specific local government study 
requirements.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
110 Methods of contraception for women of childbearing potential  
Methods  Examples  
Highly effective contraception   combination oral contraceptive pill and mini -
pill 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 
pounds or 90  kg) 
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopian tube implants (if confirmed by 
hysterosalpingogram)  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical 
sponges  
 barrier method with use of a spermic ide 
o condom with spermicide  
o diaphragm with spermicide, or  
o female condom with spermicide . 
Note: The barrier method must include use of a 
spermicide (that is, condom with spermicide, 
diaphragm with spermicide, and female condom with 
spermicide) to be considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combination of above 2, 
cervical mucus, symptothermal)  
 withdrawal  
 post coital douc he, and  
 lactational amenorrhea . 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
111 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  
Hepatic Evaluation Testing  
See Section  8.2.5  for guidance on appropriate test selection.  
The Lilly -designated central laboratory must complete the analysis of all selected testing except 
for microbiology testing.  
Local testing may be per formed in addition to central testing  when necessary for immediate 
participant management.  
Results will be reported if a validated test or calculation is available.  
Hematology  Clinical Chemistry  
Hemoglobin  Total bilirubin  
Hematocrit  Direct bilirubin  
Erythrocytes (RBCs - red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs - white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
    Neutrophils, segmented  Gamma -glutamyl transferase (GGT)  
    Lymphocytes  Creatine kinase (CK)  
    Monocytes  Other Chemistry  
    Basophils  Acetaminophen  
    Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
Ethyl alcohol (EtOH)  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin IgA (quantitative)  
 
Hepatitis A virus (HAV) testing:  Immunoglobulin IgG (quantitative)  
    HAV total antibody  Immunoglobulin IgM (quantitative)  
    HAV IgM antibody  Phosphatidylethanol (PEth)  
Hepatis B virus (HBV) testing:  Urine Chemistry  
    Hepatitis B surface antigen (HBsAg)  Drug screen  
    Hepatitis B surface antibody (anti -HBs)  Ethyl glucuronide (EtG)  
    Hepatitis B core total antibody (anti -HBc)  Other Serology  
    Hepatitis B core IgM antibody  Anti-nuclear antibody (ANA)  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
112     Hepatitis B core IgG antibody  Anti-smooth muscle antibody (ASMA) a 
    HBV DNA b Anti-actin antibody c 
Hepatis C virus (HCV) testing:  Epstein -Barr virus (EBV) testing:  
    HCV antibody      EBV antibody  
    HCV RNA b     EBV DNA b 
Hepatitis D virus (HDV) testing:  Cytomegalovirus (CMV) testing:  
    HDV antibody      CMV antibody  
Hepatitis E virus (HEV) testing:      CMV DNA b 
    HEV IgG antibody  Herpes simplex virus (HSV) testing:  
    HEV IgM antibody      HSV (Type 1 and 2) antibody  
    HEV RNA b     HSV (Type 1 and 2) DNA b 
Microbiology d Liver kidney microsomal Type 1 (LKM -1) antibody  
Culture:   
    Blood   
    Urine   
a Not required if anti -actin antibody is tested.  
b Reflex  or confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
d Assayed ONLY by investigator -designated local lab oratory; no central testing available.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
113 10.6. Appendix 6: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  
Refer to Appendix 3 for defin itions and procedures for recording, evaluating, follow -up, and 
reporting of all events.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
114 10.7. Appendix 7: Country -specific Requirements  
10.7.1.  Canada  
This section describes protocol changes applicable to adult participants at study sites  in Canada.  
This table describes the changes and provides a rationale for the changes.  
Protocol Section Number and Name  Description of the Change  Brief Rationale  
Inadvertently Enrolled Participants  New section specific to 
Canada . Information on  inadvertently 
enrolled participants added per 
Canadian  local requirements.  
The revised text described below  show s the changes applicable to adult participants at study sites 
in Canada . Deletions are identified by strikethrough format  and additions by underlined text . 
Inadvertently Enrolled Participants  
If the sponsor or investigator identifies  a participant who did not meet enrollment criteria and 
was inadvertently en rolled, then the participant should be discontinued from study intervention 
and safety follow -up should be performed as outlined in the SoA  and Section 8.3  of the protocol.   
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
115 10.7.2.  Brazil  
This section describes protocol changes applicable to adult participants at study sites in Brazil.  
This table describes the changes and provides a rationale for  the changes.  
Protocol Section Number and Name  Description of the Change  Brief Rationale  
Section 5.2. Exclusion Criteria  Exclusion criterion 28  
30 days is changed to 1 year . Resolution No. 251 (Brazil 1997).  
The National ERB  Brazil 
recommends not having a 
participan t enter a new clinical 
study  if less  than 1 year has elapsed 
since participation in another 
clinical  study of an investigational 
drug or device unless there is a 
direct benefit to the research 
participa nt. 
Section  10.1.12. Sample Retention  Biological samples will be 
stored for up to 10 years.  Compliance with Brazilian 
regulation applicable to sample 
storage, resolution CNS 441 (Brazil 
2011) . 
Patient Access to Project Benefits  New section specific to Brazil . Clarifies the sponsor responsibilities 
to comply with Resolution CNS 466 
(Brazil 2012) and RDC 38 (Brazil 
2013).  
Section 11. References  Addition of Bra zil-specific 
references  The references are specific to the 
Brazil -specific requirements.  
The revised te xt described below  show s the changes applicable to adult participants at study sites 
in Brazil . Deletions are identified by strikethrough format and additions by underlined text . 
5.2. Exclusion Criteria  
28. Are currently enrolled or have participated within the last 30 days in a clinical 
study involving an investigational intervention or any other type of medical research 
judged not to be scientifically or medically compatible with this study. If the previous 
investigational intervention has a long half -life, 3 months or 5 half -lives, whichever is 
longer, should have passed prior to Visit 1.  
Are currently enrolled in, discontinued , or completed within a period of 1 year, before 
inclusion, from a clinical study  involving an investigational intervention  or nonap proved 
use of a drug or device, or concurrently enrolled in any other type of medical research 
judged not to be scientifically or medically compatible with this study unless there is 
direct benefit to the research subject. A time period of 30 days, as indi cated by the 
protocol, must still be followed if a direct benefit to the research pa rticipa nt is identified.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
116 10.1. 12. Sample Retention  
In Brazil, the biological samples obtained within this study will be stored for up to 10 years, with 
possibility of renewal under request, followed by appropriate justification and a report with all 
activities developed with the biological samples (CNS 441/2011). The sample and any data 
generated from it can be linked back to the pa rticipa nt only by investigator site pe rsonnel. The 
duration allows the sponsor to respond to regulatory requests related to the study intervention . 
Patient Access to the Project Benefits  
In Brazil, at the end of their participation in the study, all participants must have assured access 
to the  best proven prop hylactic, diagnostic, and therapeutic methods, which may includ e 
LY3209590 or insulin degludec , identified through the study (CNS 466/2012 and RDC 38/2013) . 
11. References  
BRASIL, MINISTÉRIO DA SAÚDE. Resolução 251/1997 do Conselho Nacional de Saúde/MS: 
Normas de Pesquisa com Novos Fármacos,  Medicamentos, Vacinas e Testes Diagnósticos  
Envolvendo Seres Humanos.  
BRASIL, MINISTÉRIO DA SAÚDE. Resolução 466/2012 do Conselho Nacional da Saúde / 
MS: Diretrizes  e Normas Regulamentadoras de Pesquisas Envolvendo Seres Humanos. 
Publicado no Diário Oficial da União em 13 de junho, 2013.  
BRASIL, MINISTÉRIO DA SAÚDE. Resolução 340/2004 do Conselho Nacional da Saúde/MS: 
Diretrizes para Análise Ética e Tramitação dos Pr ojetos de Pesquisa da Área Temática 
Especial de Genética Humana.  
BRASIL, MINISTÉRIO DA SAÚDE. Resolução 441/2011 do Conselho Nacional da Saúde / 
MS: Diretrizes para análise ética de projetos de pesquisas que envolvam armazenamento de 
material biológico hum ano ou uso de material armazenado em pesquisas anteriores.  
BRASIL, MINISTÉRIO DA SAÚDE.  Resolução -RDC 38/2013 
da Agência  Nacional  deVigilância  Sanitária/MS:  Aprova  o regulamento  para os programas  de 
acesso  expandido , usocompassivo  e fornecimento  de medicamento  pós-estudo .  
 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
117 10.7.3.  Germany  
This section describes protocol changes applicable to adult participants at study sites in 
Germany.  
This table describes the changes and provides a rationale for the changes.  
Protocol Section Number and Name  Description of the Change  Brief Rationale  
7.2. Participant 
Discontinuation/Withdraw from the 
Study  
 
8.3. Adverse Events, Serious Adverse 
Events, and Product Complaints  
 
 
 Deleted references to “legally 
authorized representative,” 
“legal guardian,” “parents” . The German Drug Law 
(Arzneimittelgesetz – AMG)  with 
reference to EU Regulation 
536/2014  requires that adult 
participants act on their own 
behalf and provide their own 
written informed consent. If 
written consent is not possible , 
verbal consent with a witness is 
acceptable. No legal 
representative consent is 
accepted.  
10.8 Appendix 8: Provisions for Changes in 
Study Conduct During Exceptional 
Circumstances  Replaced references to 
“exceptional circumstances” 
with the “COVID -19 
pandemic”.  Temp orary measures may only be 
used in response to the COVID -
19 pandemic.  
The revised text described below  show s the changes applicable  to adult participants at study sites 
in Germany. Deletions are identified by strikethrough format  and additions by underlined text . 
7.2. Participant Discontinuation /Withdraw from the Study  
A participant may withdraw from the study:  
● at any time at the participant’s own request  
● at the request of the participant’s designee (for example, parents or legal 
guardian)  
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enrollment in any other clinical study involving an investigational product or 
enrollment in any other type of medical research judged not t o be scientifically or 
medically compatible with this study  
● if the participant, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the s tudy occurs prior to introduction of the new agent.  
 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
118 8.3. Adverse Events, Serious Adverse Events, and Product Complaints  
The definitions of the following events can be found in Appendix 3:  
 Adverse events (AEs)  
 Serious adverse events (SAEs)  
 Product complain ts (PCs)  
These events will be reported by the participant (or, when appropriate, by a caregiver, surrogate , 
or the participant's legally authorized representative) . 
Section 10.8.  Appendix 8: Provis ions for Changes in Study Conduct During Exceptional 
Circumstances  due to the COVID -19 Pandemic  
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership with the 
investigator.  
Exceptional circumstances  Study disruptions due to the COVID -19 pandemic  
Individual, site, or regional restrictions due to the COVID -19 pandemic Exceptional 
circumstances are rare events  that may cause disruptions to the conduct of the study. Examples 
include pandemics or natural disasters.  These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implem enting changes under exceptional circumstances  during the COVID -19 pandemic  
In an exceptional circumstance, a  After receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulations.  
After approval by local ERBs, regul atory bodies , and any other relevant local authorities, 
implementation of these exceptional circumstance  changes will not typically require additional 
notification to these groups, unless they have specific requirements in which notification is 
required , for example, upon implementation and suspension of changes. All approvals and 
notifications must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidan ce, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to conti nue safely in the study and maintaining the integrity of the study.  
Informed consent  
Additional consent from the participant will be obtained, if required, for  
 participation in remote visits, as defined in Section “Remote Visits”  
 dispensation of additional  study intervention during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
119  provision of their personal or medical information required prior to implementation of 
these activities.  
Changes in study conduct d uring exceptional circumstances  the COVID -19 pandemic  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The following changes in study conduct will not be considered protocol devi ations.  
To ensure the quality of data and the well -being of participants, it will be ensured that the 
investigator sites and their staff are following GCP principles and are meeting the sponsor 
responsibilities of Section 5 of ICH GCP. Throughout these act ivities the participant remains 
under the care of the primary investigator.  
Remote visits  
Types of remote visits  
Telemedicine:  Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments according to the SoA, if written approval is provided by the 
sponsor.  
Mobile healthcare: Healthcare visits may be performed by a mobile healthcare provider at 
locations other than the study site when participants cannot travel to the site due to an 
exceptional circumstance  the COVID -19 pandemic  if written approval is provided by the 
sponsor . 
Other alternative locations: Laboratory draws may be done at an alternate location in exceptional 
circumstances, if written approval is provided by the sponsor.  
Data capture  
In source d ocuments and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of central laboratory testing, except for HbA1c 
and serum glucose testing. Lilly -designated laboratory testing must be retained for HbA1c and  
serum glucose.  
The local laboratory must be qualified in accordance with applicable local regulations.  
Obtain local labs for safety hematology, chemistry, hormone panel, and urinalysis, when 
applicable, per the SoA. Safety labs should be obtained as speci fied in the SoA. 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
120 All labs will be reviewed by the investigators. Sign and date review of local labs per normal 
process and follow -up with the participant as needed. Results will not be recorded in the eCRF.  
Lilly Medical should be informed of any labs that  meet criteria for temporary or permanent study 
intervention  discontinuation.  
Study intervention and ancillary supplies (including participant diaries)  
When a  participant is unable to go to the site to receive study supplies during normal on -site 
visits, t he site should work with the sponsor to determine appropriate actions. These actions may 
include:  
 asking the participant to go to the site and receive study supplies from site staff 
without completion of a full study visit  
 asking the participant’s designee  to go to the site and receive study supplies on a 
participant’s behalf, and  
 arranging delivery of study supplies.  
These requirements must be met before action is taken:  
 Alternate delivery of study intervention should be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain unchanged, including 
verification of participant’s receipt of study supplies.  
 When delivering supplies to a location other th an the study site, for example, 
participant’s home, the investigator, sponsor, or both should ensure oversight of the 
shipping process to ensure accountability and product quality, that is, storage 
conditions maintained and intact packaging upon receipt.  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
Screening period guidance  
To ensure safety of study participants, laboratory values and other eligibility assessments taken 
at screening or the lead -in visits are valid for a maximum of 24 days. The following rules will be 
applied for active, nonrandomized participants whose participation in the study must be paused 
due to exceptional circumstances  the COVID -19 pandemic : 
 If screening is paused for less than 24 days from the signing of the ICF to the 
randomization visit, the participant will proceed to the next study visit per the usual 
SoA, provided that the randomization visit is conducted within 30 days from first 
screening . 
o The site should conduct the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confirmation in the source 
documentation.  
 If screening is paused for more than 24 days from signing of the ICF to the 
randomization visit, the participant must be discontinued because of screening 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
121 interruption due to an exceptional circumstance  the CO VID-19 pandemic . This is 
documented as a screen failure in the CRF.  The participant can reconsent and be 
rescreened as a new participant. The screening procedures per the usual SoA should 
be followed, starting at the screening visit to ensure participant e ligibility by the 
randomization visit.  
Adjustments to visit windows  
Whenever possible and safe to do so, as determined by the investigator’s discretion, participants 
should complete the usual SoA. To maximize the possibility that these visits can be conduc ted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study.  
The primary endpoint visit, Visit 3 1 (Week 52 ), should be completed per orig inal schedule 
whenever possible and safe to do so. However, the visit windows should be within ±7 days  
relative to the target visit date.  
For participants whose visits have extended windows, additional study intervention may need to 
be provided to avoid interruption and maintain overall integrity of the study.  
Documentation  
Changes to study conduct will be documented  
Sites will identify and document the details of how participants, visits types, and conducted 
activities were affected by exceptional circum stances  the COVID -19 pandemic . Dispensing  or 
shipment records of study intervention and relevant communications, including delegation, 
should be filed with site study records.  
Source documents at alternate locations  
Source documents generated at a location  other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
 
Section 10.10.  Appendix 10: Abbreviations and Definitions  
enter  Participants entered into a study are those who sign the informed consent form  directly 
or through their legally acceptable representatives.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
122 10.8. Appendix 8: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  
Implementation of this appe ndix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership with the 
investigator.  
Exceptional circumstances  
Exceptional circumstances are rare events  that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study pr ocedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulations.  
After approval by local ERBs, regulatory bodies , and any other relevant local authorities, 
implementation of these exceptional circumstance changes will not typically require additional 
notification to these groups, unless they have specific requirements in which notification is 
required , for example, u pon implementation and suspension of changes. All approvals and 
notifications must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to continue safely in t he study and maintaining the integrity of the study.  
Informed consent  
Additional consent from the participant will be obtained, if required, for  
 participation in remote visits, as defined in Section “Remote Visits”  
 dispensation of additional study intervention during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of their personal or medical information required prior to implementation of 
these activities.  
Changes in study conduct during e xceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
123 The following changes in study conduct will not be considered protocol deviations : 
Remote visits  
Types of remote visits  
Telemedicine:  Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments  according to the SoA , if written approval is provided by the 
sponsor.  
Mobile healthcare: Healthcare visits may be pe rformed by a mobile healthcare provider at 
locations other than the study site when participants cannot travel to the site due to an 
exceptional circumstance if written approval is provided by the sponsor . 
Other alternative locations: Laboratory draws  may be done at an alternate location in exceptional 
circumstances , if written approval is provided by the sponsor.  
Data capture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing be cause of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of ce ntral laboratory testing , except for HbA1c 
and serum glucose  testing . Lilly -designated laboratory testing must be retained for HbA1c and 
serum glucose.  
The local laboratory must be qualified in accordance with applicable local regulations.  
Obtain local labs for safety hematology, chemistry, hormone panel, and urinalysis , when 
applicable, per the SoA. Safety labs should be obtained as specified in the SoA. 
All labs will be reviewed by the investigators. Sign and date review of local labs per normal 
process and follow -up with the participant as needed. Results will not be recorded in the eCRF.  
Lilly Medical should be informed of any labs that meet criteria for temporary or permanent study 
intervention  discontinuation.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
124 Study intervention and ancillary supplies (including participant diaries)  
When a  participant is unable to go to the site to receive study supplies during normal on -site 
visits, the site should work with the sponsor to determine appropriate actions. These actions may 
include  
 asking the par ticipant to go to the site and receive study supplies from site staff 
without completion of a full study visit  
 asking the participant’s designee to go to the site and receive study supplies on a 
participant’s behalf, and 
 arranging delivery of study supplie s. 
These requirements must be met before action is taken . 
 Alternate delivery of study intervention should be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product acc ountability remain unchanged, including 
verification of participant’s receipt of study supplies.  
 When delivering supplies to a location other than the study site , for example, 
participant’s home, the investigator, sponsor, or both , should ensure oversight of the 
shipping process to ensure accountability and product quality , that is, storage 
conditions maintained and intact packaging upon receipt.  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
Screening period guidance  
To ensure safety of study participants, laboratory values and other eligibility assessments taken 
at screening or the lead -in visits are valid for a maximum of 24 days. The following  rules will be 
applied for active, nonrandomized participants whose participation in the study must be paused 
due to exceptional circumstances : 
 If screening is paused for less than 24 days from the signing of the ICF  to the 
randomization visit , the partici pant will proceed to the next study visit per the usual 
SoA, provided that the randomization visit is conducted within 30 days from first 
screening.  
o The site should conduct the next visit if the participant’s eligibility criteria are 
confirmed, and the sit e should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confirmation in the source 
documentation.  
 If screening is paused for more than 24 days from signing of the ICF  to the 
randomization visit , the participant must be discontinued because of screening 
interruption due to an exceptional circumstance.  This is documented as a screen 
failure in the CRF.  The participant can reconsent and be rescreened as a new 
participant. The screening procedures per the usual SoA should be followed, starting 
at the screening visit to ensure participant eligibility by the randomization visit.  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
125 Adjustments to visit windows  
Whenever possible and safe to do so, as determined by the investigator’s discretion, participants 
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct o f the study.  
The primary endpoint visit , Visit 31 (Week 52), should be completed per original schedule 
whenever possible and safe to do so. However, the visit windows should be within ±7 days  
relative to the target visit date.  
For participants whose visits  have extended windows, additional study intervention may need to 
be provided to avoid interruption and maintain overall integrity of the study.  
Documentation  
Changes to study conduct will be documented  
Sites will identify and document the details of how participants, visits types, and conducted 
activities were affected by exceptional circumstances. Dispensing  or shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documen ts at alternate locations  
Source documents generated at a location other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
126 10.9. Appendix 9: Abbreviations  and Defi nitions  
Term  Definition  
abuse  Use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
ADA  antidrug antibody  
AE adverse event  
ANCOVA  analysis of covariance  
authorized IMP  Applicable to the EU only : a medicinal product authorized in accordance with 
Regulation (EC) No 726/2004 or in any Member State concerned in accordance with 
Directive 2001/83/EC, irrespective of changes to the labelling of the medicinal 
product, which is used as an investigational medicinal pro duct 
authorized AxMP  Applicable to the EU only : a medicinal product authorized in accordance with 
Regulation (EC) No 726/2004, or in any Member State concerned in accordance with 
Directive 2001/83/EC, irrespective of changes to the labelling of the medici nal 
product, which is used as an auxiliary medicinal product  
AxMP  auxiliary medicinal product. See also NIMP.  
A medicinal product used for the needs of a clinical trial as described in the protocol, 
but not as an investigational medicinal product. Example s include rescue medication, 
challenge agents, agents to assess endpoints in the clinical trial, or background 
treatment. AxMP does not include investigational medicinal product (IMP) or 
concomitant medications. Concomitant medications are medications unre lated to the 
clinical trial and not relevant for the design of the clinical trial  
CGM  continuous glucose monitoring ; can refer to study procedure or analysis of 
representative CGM derived variables including but not limited to:  
 time in range from 70  to 180 mg/dL  (3.9-10 mmol/L)  and 70 to 140 mg/ dL (3.9 -7.7 
mmol /L) 
 time below range from ≥54  mg/dL  (3 mmol/L)  to <70 mg/dL  (3.9 mmol/L) , <70 
mg/dl  (3.9 mmol/L) , and <54 mg/dL (3 mmol/L)  
 time above range from >180  mg/dL  (10 mmol/L)  to ≤250 mg/dL  (13.9 mmol/L ) 
and >250 mg/dL (13.9 mmol/L)  
 daily average glucose  
 glucose management indicator  
 between - and within-day glucose variability  
 low blood glucose index , high blood glucose index; blood glucose risk indicator ; 
and 
 ambulatory glucose profiles with interquartile ranges . 
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery s ystem  
compliance  Adherence to all study -related, good clinical practice, and applicable regulatory 
requirements  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
127 CRF  case report form; a printed, optical, or electronic document designed to record all of 
the protocol -required information to be reported to  the sponsor for each trial 
participant  
DMC  data monitoring committee ; a data-monitoring committee is a group of independent 
scientists who are appointed to monitor the safety and scientific integrity of a human 
research intervention and to make recommendations to the sponsor regarding the 
stopping of a study for efficacy, or for harms, or for futility. The composition of the 
committee is dependent upon the scientific skills and knowledge required for 
monitoring the particular study  
DPP -4 dipepti dyl peptidase -4 
Device deficiencies  equivalent to product complaint  
EDC  electronic data capture  
eGFR (CKD -EPI)  estimated glomerular filtration rate (chronic kidney disease epidemiology 
collaboration ) 
enroll  The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment  
enter  Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives  
ERB  Ethical Review Board  
FBG  fasting blood glucose  
GCP  good clinical practice  
GLP -1 glucagon -like peptide -1 
IB Investigator’s Brochure  
ICF informed consent form  
ICH  International Council for Harmonisation  
IEC Independent Ethics Committees  
IMP  investigational medicinal product  
A medicinal product , which is being tested or used as a reference, including as a 
placebo, in a clinical trial.  
See also “ investigational product .” 
informed consent  A process by which a participant voluntarily confirms their willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the participant’s decision to participate. Informed consent is documented by 
means of a written, signed , and dated informed consent form  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
128 interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment 
groups, that is conducted before the final reporting database is created  or locked  
investigational 
product  A pharmaceutical form of an activ e ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthor ized indication, or marketed products used to 
gain further information about the authorized form  
IRB Institutional Review Boards  
IWRS  interactive web -response system  
medication error  Errors in the prescribing, dispensing, or administration of a study intervention, 
regardless of whether or not the medication is administered to the participant or the 
error leads to an AE. Medication error generally involve s a failure to uphold 1 or more 
of the 5 “rights” of medication use: the right participant, the righ t drug, the right dose, 
right route, and at the right time.  
In addition to the core 5 rights, the following may also represent medication errors:  
• dose omission associated with an AE or a product complaint  
• dispensing or use of expired medication  
• use of medication past the recommended in -use date  
• dispensing or use of an improperly stored medication  
• use of an adulterated dosage form or administration technique inconsistent with the 
medication ’s labeling (for example, Summary of Product Characteristics, IB, local 
label, and protocol), or  
• shared use of cartridges, prefilled pens, or both.  
misuse  use of a study intervention for self -treatment that either is inconsistent with the 
prescribed dosi ng regimen, indication, or both, or is obtained without a prescription  
MMRM  mixed -model repeated measures  
NIM  noninferiority margin  
NIMP  non-investigational medicinal product  
A medicinal product used for the needs of a clinical trial as described in the  protocol, 
but not as an investigational medicinal product. Examples include rescue medication, 
challenge agents, agents to assess endpoints in the clinical trial, or background 
treatment.  
See AxMP.  
participant  equivalent to CDISC term “subject”: an indi vidual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control  
PC product complaint  
PK/PD  pharmacokinetics/pharmacodynamics  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
129 PT-INR prothrombin time, INR  
QTc  corrected QT interval  
SAE  serious adverse event  
SAP  statistical analysis plan  
screen  The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study  
SGLT2  sodium -glucose cotransporter 2  
SIM -Q Simplicity of Diabetes Treatment Questionnaire  
SMBG  self-monitoring of blood glucose  
SU sulphon ylureas  
T1D  Type 1 diabetes  
T2D  Type 2 diabetes  
TEADA  treatment -emergent ADA  
TEAE  treatment -emergent adverse event: an untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens 
relative to the pretreatment state, and does not necessarily have to have a causal 
relationship with this treatment  
TRIM -D Treatment -Related Impact Measure – Diabetes  
 
  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
130 10.10.  Appendix 1 0: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment [a]: (15 Feb 2022 ) 
This amendment is considered to be nonsubstantial. Overall Rationale for the Amendment  
The overall rationale for the changes implemented in the protocol amendment is to update the 
insulin degludec dose adjustments so that it will more closely reflect those for LY3209590.  
Section # and Name  Description of Change  Brief Rationale  
Section 1.1 Synopsis  Visit and Week numbers were 
changed and an additional row 
was added to the table to indicate 
that insulin degludec dose 
adjustments may occur every 4 
weeks after Week 12 (Visit 15)  Table was modified to reflect the 
changes in insulin degludec dose 
adjustments  
Section 1.2 Schema  Added “CGM Visits” to Safety 
Follow -Up section  Correction -this section was 
missing in original schema  
Section 1.3.1 
Schedule of 
Activities  Demographics comment -replaced 
“gender” with “sex”  Preferred terminology  
Section 1.3.1 and 
1.3.2  Schedule of 
Activities  Added the following text to ECG 
comment -“ECGs will be 
performed prior to collection of 
any blood samples”  For clarification  
Section 4.3 
Justification for Dose  Text was changed to indicate that 
insulin degludec dose adjustments 
shou ld occur weekly from Visits 
4 to 15 (Weeks 1 to 12) and then 
every 4 weeks thereafter.   The text was modified to be 
consistent with LY3209590 dose 
adjustments  
Section 6.1 Study 
Intervention(s) 
Administered  Added the following text to 
Anatomical Location o f 
Injections –“ Injections may be 
administered in the abdomen, 
thigh, arm, or buttock. Refer to 
the IFU for complete instructions 
on dose administration.  Anatomical location of insulin 
injections added to address FDA 
feedback to include acceptable 
anatomic al locations for insulin 
administration in the protocol  
Section 6.5.1.2 
LY3209590 Dose 
Adjustment Based on 
FBG  Addition of the following 
sentence:  
“If the participant experienced 
any documented BG ≤70  mg/dL 
(≤3.9  mmol/L) in the previous To emphasize that, in the 
occurrence of a hypoglycemia 
event <70, insulin doses should 
not increase  
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
131 week, the dose should not be 
increased”  
Section 6.5.2.1 
Insulin Degludec 
General Dosing 
Information by Visit  Visit and Week numbers were 
changed and an additional row 
was added to the table to indicate 
that insulin degludec dose 
adjustments may occur every 4 
weeks after Week 12 (Visit 15)  Table was modified to reflect the 
changes in insulin degludec dose 
adjustments  
Section 6.5.2.2  
Insulin Degludec 
Dose Adjustment 
Based o n FBG  Addition of the following 
sentence:  
“If the participant experienced 
any documented BG ≤70  mg/dL 
(≤3.9  mmol/L) in the previous 
week, the dose should not be 
increased”  To emphasize that, in the 
occurrence of a hypoglycemia 
event <70, insulin doses shou ld 
not increase  
Section 9.3.6.1 
Pharmacokinetic and 
Pharmacodynamic 
Analyses  Replaced “gender” with “sex”  Preferred terminology  
Throughout  Minor editorial revisions  Minor, therefore, have not been 
summarized  
 
 
 
Approved on 13 May 2022 GMT
CONFIDENTIAL  I8H-MC-BDCX  (b) 
132 11. References  
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple 
test procedures. Statist Med. 2009;28:586 -604. https://doi.org/10. 1002/sim.3495 . 
Bretz F, Posch M, Glimm E, et al. Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests. Biomet J. 2011;53(6):894 -913. 
https://onlinelibrary.wiley.com/doi/pdf/10.1002/bimj.201000239 . 
EuroQol Research Foundation. EQ-5D-5L user guide, version 3.0. Updated September 2019. 
Accessed 01 February 2022.  https://euroqol.org/publications/user -guides . 
Maruish ME, ed itor. User’s Manual for the SF -36v2 Health Survey . 3rd ed. Lincoln, RI: Quality 
Metric Incorporated; 2011.  
Rubin DB. Multiple Imputation for Nonresponse in Surveys . New York: Wiley; 1987 . 
Approved on 13 May 2022 GMT
Si g nat ure Pa ge f or V V- C LI N- 0 4 0 2 0 6 v 2. 0 
Si g nat ure Pa ge f or V V- C LI N- 0 4 0 2 0 6 v 2. 0 A p pr o val 
Me dical Direct or 
1 3- Ma y- 2 0 2 2 1 6: 1 6: 5 0 G M T + 0 0 0 0 
A p pr o val 
Statisticia n 
1 3- Ma y- 2 0 2 2 1 6: 1 9: 4 7 G M T + 0 0 0 0 
A p pr o ve d o n 1 3 Ma y 2 0 2 2 G M T P P D 
P P D 